

# **Polygenic risk for immuno-metabolic markers and specific depressive symptoms: A multi-sample network analysis study**

Nils Kappelmann<sup>1,2</sup>, Darina Czamara<sup>1</sup>, Nicolas Rost<sup>1,2</sup>, Sylvain Moser<sup>1,2</sup>, Vanessa Schmoll<sup>1</sup>, Lucia Trastulla<sup>1</sup>, Jan Stochl<sup>3,4</sup>, Susanne Lucae<sup>5</sup>, CHARGE inflammation working group, Elisabeth B. Binder<sup>1</sup>, Golam M. Khandaker<sup>3,6,7,8,\*</sup>, & Janine Arloth<sup>1,9,\*</sup>

<sup>1</sup>Department of Translational Research in Psychiatry, Max-Planck-Institute of Psychiatry, Munich, Germany

<sup>2</sup>International Max Planck Research School for Translational Psychiatry (IMPRS-TP), Munich, Germany

<sup>3</sup>Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom

<sup>4</sup>Department of Kinanthropology, Charles University, Prague, Czech Republic

<sup>5</sup>Max-Planck-Institute of Psychiatry, Munich, Germany

<sup>6</sup>Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, United Kingdom

<sup>7</sup>MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom

<sup>8</sup>Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom

<sup>9</sup>Institute of Computational Biology, Helmholtz Zentrum Munich, Neuherberg, Germany

\*joint senior authors

## **Corresponding author:**

Nils Kappelmann  
Max-Planck-Institute of Psychiatry  
Kraepelinstraße 2-10  
80804 Munich, Germany

Email: [nils\\_kappelmann@psych.mpg.de](mailto:nils_kappelmann@psych.mpg.de); [n.kappelmann@gmail.com](mailto:n.kappelmann@gmail.com)

**Abstract word count:** 399

**Manuscript word count:** 6,306

**Tables and Figures:** 2 Tables and 3 Figures

**Online Supplementary Tables and Figures:** 7 Tables and 9 Figures

## 1 **ABSTRACT**

### 2 ***Background***

3 About every fourth patient with major depressive disorder (MDD) shows evidence of systemic  
4 inflammation. Previous studies have shown inflammation-depression associations of multiple  
5 serum inflammatory markers and multiple specific depressive symptoms. It remains unclear,  
6 however, if these associations extend to genetic/lifetime predisposition to higher inflammatory  
7 marker levels and what role metabolic factors such as Body Mass Index (BMI) play. It is also  
8 unclear whether inflammation-symptom associations reflect direct or indirect associations, which  
9 can be disentangled using network analysis.

### 10 ***Methods***

11 This study examined associations of polygenic risk scores (PRSs) for immuno-metabolic markers  
12 (C-reactive protein [CRP], interleukin [IL]-6, IL-10, tumour necrosis factor [TNF]- $\alpha$ , BMI) with  
13 seven depressive symptoms in one general population sample, the UK Biobank study  
14 (n=110,010), and two patient samples, the Munich Antidepressant Response Signature (MARS,  
15 n=1,058) and Sequenced Treatment Alternatives to Relieve Depression (STAR\*D, n=1,143)  
16 studies. Network analysis was applied jointly for these samples using fused graphical least  
17 absolute shrinkage and selection operator (FGL) estimation as primary analysis and, individually,  
18 using unregularized model search estimation. Stability of results was assessed using  
19 bootstrapping and three consistency criteria were defined to appraise robustness and replicability  
20 of results across estimation methods, network bootstrapping, and samples.

### 21 ***Results***

22 Network analysis results displayed to-be-expected PRS-PRS and symptom-symptom associations  
23 (termed edges), respectively, that were mostly positive. Using FGL estimation, results further

24 suggested 28, 29, and six PRS-symptom edges in MARS, STAR\*D, and UK Biobank samples,  
25 respectively. Unregularized model search estimation suggested three PRS-symptom edges in the  
26 UK Biobank sample. Applying our consistency criteria to these associations indicated that only  
27 the association of higher CRP PRS with greater changes in appetite fulfilled all three criteria.  
28 Four additional associations fulfilled at least two consistency criteria; specifically, higher CRP  
29 PRS was associated with greater fatigue and reduced anhedonia, higher TNF- $\alpha$  PRS was  
30 associated with greater fatigue, and higher BMI PRS with greater changes in appetite and  
31 anhedonia. Associations of the BMI PRS with anhedonia, however, showed an inconsistent  
32 valence across estimation methods.

### 33 ***Conclusions***

34 Genetic predisposition to higher systemic inflammatory markers are primarily associated with  
35 somatic/neurovegetative symptoms of depression such as changes in appetite and fatigue,  
36 consistent with previous studies based on circulating levels of inflammatory markers. We extend  
37 these findings by providing evidence that associations are direct (using network analysis) and  
38 extend to genetic predisposition to immuno-metabolic markers (using PRSs). Our findings can  
39 inform selection of patients with inflammation-related symptoms into clinical trials of immune-  
40 modulating drugs for MDD.

41

42 ***Keywords:*** Depression; Depressive Symptoms; Inflammation; C-reactive protein; Body Mass  
43 Index; Interleukin 6; Interleukin 10; Tumour Necrosis Factor- $\alpha$ ; Network Analysis

## 44 INTRODUCTION

45 Recent findings suggest that every fourth patient with Major Depressive Disorder (MDD) shows  
46 evidence of systemic, low-grade inflammation as indicated by elevated (>3mg/L) C-reactive  
47 protein (CRP) concentrations (Osimo et al., 2019). This association has been supported by cross-  
48 sectional case-control studies synthesised in multiple meta-analyses (Dowlati et al., 2010;  
49 Goldsmith et al., 2016; Haapakoski et al., 2015; Howren et al., 2009; Köhler et al., 2017) as well  
50 as longitudinal studies (Khandaker et al., 2014; Lamers et al., 2020; Mac Giollabhui et al., 2020).  
51 Clinically, patients with evidence of inflammation do not respond as well to standard  
52 monoaminergic and psychotherapeutic treatments (Liu et al., 2020; Lopresti, 2017). These  
53 patients may, however, benefit from alternative treatment with immune-modulating drugs  
54 (Kappelmann et al., 2018; Köhler-Forsberg et al., 2019; Wittenberg et al., 2020). To prioritise  
55 drug and patient selection for clinical trials, it is crucial to further understand immunological and  
56 clinical complexity of inflammation-symptom associations, which may allow shortlisting of  
57 promising immunotherapeutic drug targets and could highlight patients with a profile of  
58 inflammation-related depression.

59 Regarding immunological complexity, studies have reported various associations of serum  
60 inflammatory proteins with depression, including among others CRP, interleukin (IL)-6, IL-10,  
61 and tumour necrosis factor (TNF)- $\alpha$  (Goldsmith et al., 2016; Haapakoski et al., 2015; Köhler et  
62 al., 2017). Evidence from in-depth immunophenotyping further suggests that there may be  
63 distinct subgroups of inflammation-related depression as shown by immune cell count clustering  
64 and transcriptome analyses (Cattaneo et al., 2020; Lynall et al., 2020). These studies suggest that  
65 elevated serum levels of inflammatory markers are associated with depression, but associations of  
66 depression with genetic/lifetime predisposition to higher inflammatory markers has been studied

67 less frequently and primarily for CRP (Badini et al., 2020; Kappelmann et al., 2021; Milaneschi  
68 et al., 2017b, 2016). Elevated serum levels of inflammatory markers also conflate tonic and  
69 phasic levels of inflammatory markers while genetic/lifetime predisposition to inflammatory  
70 markers specifically maps their tonic levels. This differentiation could be relevant as highlighted  
71 by research into tonic versus phasic dopamine levels (see Bilder et al., 2004), whereby tonic  
72 levels regulate the amplitude of the phasic response, which has unique consequences for  
73 downstream signalling. Lastly, inflammatory markers such as CRP are influenced by metabolic  
74 factors (Timpson et al., 2011), which may causally underlie some inflammation-symptom  
75 associations (Kappelmann et al., 2021), so a combined investigation of immuno-metabolic factors  
76 is needed to disentangle their etiological roles.

77 Regarding clinical complexity, most prior research has restricted its investigation of the  
78 inflammation-depression association to complexity on one side, that is focusing on multiple  
79 immune markers (e.g., cell counts/ serum cytokine levels) while studying a composite depression  
80 phenotype (Goldsmith et al., 2016; Haapakoski et al., 2015; Köhler et al., 2017) or focusing on  
81 multiple depressive symptoms or symptom groups in the context of a single inflammatory marker  
82 (mostly CRP) (Badini et al., 2020; Jokela et al., 2016; Köhler-Forsberg et al., 2017; Lamers et al.,  
83 2020, 2019; White et al., 2017). Among studies focusing on individual symptoms, results have  
84 highlighted associations of inflammatory markers with specific depressive symptoms of fatigue,  
85 changes in appetite, anhedonia, and suicidality (Badini et al., 2020; Chu et al., 2019; Jokela et al.,  
86 2016; Kappelmann et al., 2021; Köhler-Forsberg et al., 2017; Lamers et al., 2020, 2018;  
87 Milaneschi et al., 2017a; Simmons et al., 2018; White et al., 2017). However, most of these  
88 studies have considered associations of inflammatory markers with each depressive symptom in  
89 isolation (Chu et al., 2019; Jokela et al., 2016; Kappelmann et al., 2021; Köhler-Forsberg et al.,  
90 2017; Lamers et al., 2018; White et al., 2017). Although these prior approaches have led to

91 important findings, they cannot address potential causal interactions between symptoms, thus  
92 conflate evidence for indirect and direct associations. For example, analyses of isolated  
93 symptoms could hypothetically provide evidence for associations of CRP with both fatigue and  
94 sleep problems even if CRP was only indirectly associated with fatigue *via* its effect on sleep  
95 problems. A network-based approach provides one means of disentangling such direct from  
96 indirect inflammation-symptom associations.

97 Network theory and related analysis techniques have recently been put forward to accommodate  
98 the symptomatic complexity of mental disorders (Borsboom, 2017). Network theory proposes  
99 putative causal interactions between symptoms (e.g., fatigue *causing* concentration problems  
100 *causing* low mood), which could result in self-reinforcing vicious symptom cycles triggering and  
101 maintaining mental disorders. Such associations have been investigated in an increasing amount  
102 of studies on psychological symptom networks (Contreras et al., 2019; Robinaugh et al., 2020).  
103 To accommodate etiological factors beyond symptoms, however, recent work has proposed an  
104 expansion of symptom networks to so-called ‘multi-plane’ networks, for instance also including  
105 genetic, metabolic, immunological, or environmental variables (Guloksuz et al., 2017). To our  
106 knowledge, so far, two studies have evaluated such multi-plane networks in the context of  
107 inflammation and depression by jointly analysing serum CRP (plus IL-6 & TNF- $\alpha$  in the study of  
108 Fried et al., 2019), BMI, and potential covariates with individual depressive symptoms (Fried et  
109 al., 2019; Moriarity et al., 2020a). The most consistently replicated findings between these two  
110 studies suggested unique associations of CRP with fatigue and changes in appetite. A third study  
111 has recently also provided evidence that the symptom structure itself was a function of CRP  
112 levels; that is, interconnections between symptoms were moderated by CRP (Moriarity et al.,  
113 2020b). All of these previous studies were based on serum markers for inflammatory proteins,  
114 however, reflective of acutely elevated inflammatory activity. Therefore, it remains unclear if

115 inflammation-symptom associations generalise to genetic/lifetime predisposition to higher  
116 immuno-metabolic marker levels.

117 In the present study, we explored associations of polygenic risk scores (PRSs) for four major pro-  
118 and anti-inflammatory markers (i.e., CRP, IL-6, IL-10, & TNF- $\alpha$ ) and Body Mass Index (BMI),  
119 as a metabolic marker, with individual depressive symptoms using a multi-sample, multi-plane  
120 network analysis approach. We evaluated associations in three large samples including the  
121 inpatient Munich Antidepressant Response Signature (MARS) study (n=1,058), the outpatient  
122 Sequenced Treatment Alternatives to Relieve Depression (STAR\*D) study (n=1,143), and the  
123 general population UK Biobank cohort (n=110,010) (Hennings et al., 2009; Rush et al., 2004;  
124 Sudlow et al., 2015). This investigation aimed to contribute to the study of inflammation and  
125 depression by simultaneously addressing (i) combined immunological and symptom complexity  
126 (using network analysis), (ii) unclarity regarding the influence of genetic/lifetime predisposition  
127 to higher immuno-metabolic marker levels on depression (defining immuno-metabolic markers  
128 using PRSs), and (iii) issues of replicability and generalisability (testing associations in one large  
129 general population and two clinical samples).

## 130 **METHODS**

131 An overview of the study design and analytic procedure is presented in Figure 1.

132 -Figure 1-

### 133 **Study samples**

134 The Munich Antidepressant Response Signature (MARS) study was a naturalistic, observational  
135 study of inpatients with major depressive disorder (MDD) or bipolar disorder conducted between  
136 2000 and 2015 in three Southern German hospitals (Hennings et al., 2009). Based on an original  
137 sample of 1,411 patients, the present study included 1,058 patients of European decent with an  
138 ICD diagnosis of MDD (F32 and F33 codes) and genetic and depressive symptom data.

139 The STAR\*D trial (identifier: NCT00021528) was a multisite, multistep, randomised controlled  
140 trial (RCT), conducted from 2000 to 2004, evaluating different treatment options and sequences  
141 for outpatients suffering from DSM-IV MDD without psychotic features (Rush et al., 2004).

142 Based on an original sample of 1,953 patients who took part in the STAR\*D genetics study, the  
143 present study included 1,143 individuals of European decent with genetic and depressive  
144 symptom data.

145 The UK Biobank is a general population cohort including more than 500,000 individuals,  
146 recruited from 2006 to 2010, with genotyping and in-depth phenotyping information (Bycroft et  
147 al., 2018). More than 150,000 individuals from the initial sample took part in a follow-up mental  
148 health survey (Davis et al., 2020) and we included a subset of 110,010 individuals that were of  
149 European decent and had available genetic and depressive symptom data.



150 ***Ethics approval and informed consent***

151 MARS received local ethics approval from Ludwig Maximilians University Munich (Hennings et  
152 al., 2009). STAR\*D received ethics approval from 14 participating institutional review boards, a  
153 National Coordinating Center, a Data Coordinating Center, and the Data Safety and Monitoring  
154 Board at the National Institute of Mental Health (Rush et al., 2006, 2004). The UK Biobank study  
155 received ethics approval from North West Centre for Research Ethics Committee and Human  
156 Tissue Authority research tissue bank (Bycroft et al., 2018); this project was approved under  
157 project no. 26999. All three studies collected informed consent from participants prior to study  
158 participation.

159 **Depressive symptom assessment**

160 Depressive symptoms were assessed differently across the three samples. MARS and STAR\*D  
161 studies used the observer-rated Hamilton Rating Scale for Depression (HAM-D) (Hamilton,  
162 1986) while the UK Biobank study used the self-report Patient Health Questionnaire (PHQ)-9  
163 (Löwe et al., 2004). From these questionnaires, we selected seven depressive symptoms for joint  
164 analyses across samples. These symptoms included completely overlapping symptoms of  
165 depressed mood, anhedonia, fatigue, and suicidality, but also partially overlapping symptoms of  
166 sleep problems, changes in appetite, and psychomotor changes. Supplementary Table 1 provides  
167 an item-level overview of depressive symptoms and Supplementary Table 2 displays symptom  
168 coding, where this differed from original Likert scale ratings.

169 Regarding partially overlapping symptoms of sleep problems, changes in appetite, and  
170 psychomotor changes, the PHQ-9 only assesses information on conflated symptoms (e.g.,  
171 insomnia and hypersomnia are conflated to sleep problems) while the HAM-D incorporates  
172 disaggregated symptoms. To harmonise these symptom data for retention in network analyses,

173 we conflated HAM-D symptoms of psychomotor retardation and agitation to “psychomotor  
174 changes”. For sleep problems and changes in appetite (available in the PHQ-9), only insomnia  
175 and loss of appetite are available in the HAM-D, so we included both conflated and  
176 unidirectional symptoms in network analyses as previous studies have specifically highlighted  
177 associations of inflammation with these symptoms (Jokela et al., 2016; Milaneschi et al., 2017b).  
178 We reasoned that comparative appraisal of associations, for example with changes in appetite and  
179 loss of appetite, could give further indications on potential specificity of associations to symptom  
180 directions, as observed in previous reports (Kappelmann et al., 2021; Milaneschi et al., 2021b,  
181 2021a).

182 We also note that we have not included items of “guilt or self-blame” from the respective studies  
183 in our analyses as we considered the item content of HAM-D and PHQ-9 too distinct.  
184 Specifically, the HAM-D conflates feelings of guilt with delusions of guilt and death, thus  
185 moving towards psychotic symptomatology. Contrary to this, the PHQ-9 also includes “feelings  
186 of inadequacy” about oneself, which are not covered by the HAM-D item.

### 187 **Genotyping, quality control and imputation**

188 We provide detailed information on genotyping, quality control and imputation procedures in the  
189 Supplementary Methods. Briefly, genotyping in the MARS study was conducted using three  
190 genotyping arrays across the recruitment period (see Supplementary Figure 1), the Illumina 610k  
191 (n=548), Illumina OmniExpress (n=284) and Illumina GSA (n=226) arrays. In STAR\*D,  
192 genotyping was conducted using the Affymetrix Human Mapping 500K Array Set (n=979) and  
193 the Affymetrix Genome-Wide Human SNP Array 5.0 (n=969) that displayed a concordance of  
194 >99%; described in detail by Garriock *and colleagues* (2010). In the UK Biobank study, samples  
195 were genotyped on the UK BiLEVE Axiom Array or the Affymetrix UK Biobank Axiom Array

196 (Bycroft et al., 2018). Following imputation in all samples, single nucleotide polymorphisms  
197 (SNPs) with info-metric>0.6, minor allele frequency (MAF)>1%, genotyping missingness<2%,  
198 and no deviation from Hardy-Weinberg Equilibrium (MARS & STAR\*D:  $P>1e^{-5}$ ; UK Biobank:  
199  $P>1e^{-7}$ ) were retained.

## 200 **Polygenic risk scores**

### 201 *Immuno-metabolic marker selection and GWAS data sources*

202 PRSs for CRP, IL-6, IL-10, TNF- $\alpha$ , and BMI were computed based on available summary  
203 statistics from genome-wide association studies (GWAS; Ahola-Olli et al., 2017; Ligthart et al.,  
204 2018; Locke et al., 2015). These inflammatory markers were selected, because (i) they showed  
205 robust differences in case-control studies; (ii) CRP, IL-6, and TNF- $\alpha$  have been the most  
206 frequently investigated inflammatory markers overall in the context of depression; and (iii) IL-10  
207 was the most frequently studied anti-inflammatory cytokine, so could be informative on direction  
208 of associations between depressive symptoms and innate immune activity (Köhler et al., 2017;  
209 Osimo et al., 2019). BMI was selected as the most frequently investigated metabolic marker.

210 GWAS data for CRP were obtained from a large GWAS of 88 studies including 204,402  
211 individuals of European decent (Ligthart et al., 2018). GWAS data for IL-6, IL-10, and TNF- $\alpha$   
212 were obtained from a GWAS of 8,293 Finns (Ahola-Olli et al., 2017); of note, Finns have  
213 Siberian ancestry (Lamnidis et al., 2018), which leads to a divergence from European ancestry of  
214 our analytic samples. GWAS data for BMI were obtained from the Genetic Investigation of  
215 Anthropometric Traits (GIANT) consortium that included up to 322,154 individuals of European  
216 decent (Locke et al., 2015).

217 ***PRS computation***

218 PRSs can be computed by summing the GWAS association estimates of risk alleles for each  
219 individual. Classically, this summation is done using an approach termed “clumping and  
220 thresholding” (C+T), which first reduces summary statistics to independent SNPs and then  
221 applies one or multiple thresholds (usually based on P-values) to restrict summation to SNPs with  
222 high evidence for associations with phenotypes (Choi et al., 2020). As the optimal threshold for  
223 the C+T approach is unknown and should ideally be estimated in a separate dataset with available  
224 phenotype data, we computed PRSs using the Bayesian regression and continuous shrinkage  
225 priors (PRS-CS) approach, which has been shown to perform similar to or outperform other PRS  
226 computation approaches such as C+T (Ge et al., 2019; Ni et al., 2020).

227 PRS-CS takes a linkage disequilibrium (LD) reference panel into account (we used European  
228 ancestry data from 1000 Genomes Project phase 3 samples) to update SNP effect sizes in a  
229 blocked fashion, thus providing accurate LD adjustment. We pre-specified the global shrinkage  
230 parameter  $\lambda$  using suggested defaults for less polygenic ( $\lambda=1e^{-4}$ ) and more polygenic ( $\lambda=1e^{-2}$ )  
231 phenotypes as  $\lambda=1e^{-4}$  for CRP, IL-6, IL-10, and TNF- $\alpha$ , and as  $\lambda=1e^{-2}$  for BMI; see details in  
232 Supplementary Methods. Following PRS computation in individual samples, polygenic scores  
233 were corrected for age, sex, and the first two genotyping principal or multidimensional scaling  
234 (MDS) components using linear regression; two genotyping principal or MDS components were  
235 selected as visual inspection of component inter-correlations did not suggest evidence for  
236 population stratification. Genotyping MDS components were computed based on raw Hamming-  
237 distances in MARS and STAR\*D, and using principal component analysis on high-quality,  
238 unrelated individuals in the UK Biobank sample (Bycroft et al., 2018). PRSs in MARS were  
239 additionally corrected for the genotyping array. Following computation, higher PRSs reflect  
240 higher genetic predisposition to respective immuno-metabolic phenotype levels.

241 ***PRS evaluation***

242 In Supplementary Table 3, we provide the number of SNPs included in PRS computation in each  
243 sample, which was approximately around one million SNPs for each phenotype-sample  
244 combination. The proportion of SNP overlap between samples (for the same phenotype) was  
245  $>0.89$  suggesting that mostly overlapping SNPs contributed to PRSs (Supplementary Table 4).  
246 Taking these overlapping SNP sets, correlations between the posterior SNP effect sizes between  
247 samples were large for CRP (Pearson's  $r$  range: 0.69-0.76) and BMI (Pearson's  $r$  range: 0.79-  
248 0.80) and relatively smaller for IL-6, IL-10, and TNF- $\alpha$  (Pearson's  $r$  range: 0.41-0.46; see  
249 Supplementary Table 5). This suggests polygenic risk was quantified more similarly across  
250 samples for CRP and BMI as compared to IL-6, IL-10, and TNF- $\alpha$ .

251 We quantified the impact that pre-specification of the hyperparameter  $\lambda$  had on resulting PRSs,  
252 which was likely small (Supplementary Table 6). Specifically, PRSs with pre-specified  $\lambda$   
253 exhibited large correlations with PRSs based on automatic learning of  $\lambda$  from GWAS summary  
254 data (termed PRS-CS-auto in the literature; Pearson's  $r$  range: 0.82-0.98). Furthermore,  
255 moderate-to-large correlations remained to PRSs based on extreme grid search boundary values  
256 of  $\lambda$  (Pearson's  $r$  range: 0.47-0.93).

257 Since MARS utilised three different genotyping arrays, we verified that our approach of  
258 combining data from these arrays into one sample was justified before proceeding with the main  
259 analysis (see Supplementary Methods and Supplementary Figures 2 and 3).

260 **Network analysis**

261 ***Estimation***

262 Network analysis was conducted using *R* software (version 4.0.3; R Core Team, 2017). In  
263 network analysis, unique associations between variables reflect partial correlations and are  
264 termed ‘edges’. Variables in the network are referred to as ‘nodes’.

265 Network models can be broadly categorised into regularized and unregularized models, that have  
266 distinct advantages and disadvantages. Regularised models apply penalties that shrink edges  
267 towards zero. This has the advantage that it results in sparser and more parsimonious network  
268 models as small edges can be set exactly to zero. Contrary to this, non-regularized models do not  
269 apply such a penalty while still controlling the false positive rate and recent studies have  
270 suggested that unregularized models perform better in estimating psychological symptom  
271 networks and multi-plane immunopsychiatric networks than regularized network models  
272 (Moriarity et al., 2020a; Williams et al., 2019). A disadvantage of unregularized models,  
273 however, is that they are currently only suitable for network estimation of individual  
274 samples/datasets. Contrary to this, regularised models have recently been adapted for application  
275 in multi-sample contexts using so-called fused graphical LASSO (FGL) estimation. FGL  
276 estimation allows synthesising data across multiple samples, which increases statistical power.

277 Based on these respective advantages and disadvantages, we have decided to use a regularized  
278 network model as primary analysis, which maximises statistical power due to the multi-sample  
279 design of our study. As unregularized models are preferable for estimation of individual samples  
280 and may be better suited to retrieve multi-plane edges, however, we also apply unregularized  
281 network estimation as secondary analysis.

282 In primary analyses, networks were estimated using FGL estimation as implemented in the  
283 *EstimateGroupNetwork* package (version 0.2.2; Costantini et al., 2020, 2019; Danaher et al.,

284 2014). FGL estimation relies on the two tuning parameters  $\lambda_1$ , which penalizes network density,  
285 and  $\lambda_2$ , which penalizes edge differences across samples. Values for these tuning parameters were  
286 selected using 10-fold cross-validation to optimise the Bayesian Information Criterion (BIC). As  
287 recommended, we set weights for the importance of each sample as ‘equal’ to ascertain that a  
288 single sample would not dominate estimation (Danaher et al., 2014).

289 As secondary analysis, we estimated unregularized networks for each sample individually using  
290 the gaussian graphical stepwise model selection (“ggModSelect”) algorithm implemented in the  
291 *qgraph* package (version 1.6.5; Epskamp et al., 2012) based on Spearman correlations and  
292 starting from an empty model. Throughout results, we refer to this estimation strategy as  
293 “unregularized model search” or “model search” for simplification.

#### 294 *Node predictability*

295 We also estimated node predictability, which describes the amount of variance in a node that is  
296 explained by all other nodes in the network, so can be interpreted akin to  $R^2$  (Haslbeck and Fried,  
297 2017). Node predictability cannot be inferred from FGL or model search networks as it requires a  
298 node-wise estimation approach. Therefore, we used a mixed graphical model as a third estimation  
299 strategy as implemented in the *mgm* package (version 1.2-10), selecting tuning parameter  $\lambda$  based  
300 on BIC optimisation in 10-fold cross-validation (Haslbeck and Waldorp, 2020). Of note, this  
301 model was only used to infer node predictability, which provides additional information on  
302 network density and sample comparability. However, we do not report any individual edge  
303 estimates based on this model as FGL estimation and unregularized model search are better  
304 suited for our study aims.

305 ***Visualisation***

306 Networks were visualised with the *qgraph* package using an average layout estimated with the  
307 Fruchterman-Reingold algorithm for the FGL networks. This algorithm places nodes close to  
308 each other that are connected by large edges (Epskamp et al., 2012). While this simplifies  
309 network appraisal, it is important to note that nodes and edges should not be interpreted based on  
310 their relative position within the network, which can be unstable.

311 ***Stability***

312 To evaluate stability of estimated networks, we assessed accuracy of edge estimates using  
313 bootstrapping strategies. Specifically, for FGL networks 500 bootstrapped samples with  
314 replacement were drawn, and FGL networks re-estimated, using the implementation in the  
315 *EstimateGroupNetwork* package (Costantini et al., 2020). For unregularized model search  
316 estimation, the same procedure was applied using non-parametric bootstrapping procedures  
317 implemented in the *bootnet* package (version 1.4.3; Epskamp et al., 2018).

318 ***Interpretation***

319 We interpreted estimated networks based on the presence, stability, and replicability of edges as  
320 defined using three consistency criteria. First, we tested if edges were nonzero in FGL networks  
321 as well as nonzero and directionally consistent in >50% of bootstrapped analyses (consistency  
322 criterion 1) akin to a previous PRS-symptom network study in psychosis by Isvoranu *and*  
323 *colleagues* (2020). Second, we tested if edges between PRSs and symptoms replicated (according  
324 to criterion 1) across FGL networks of the three samples (consistency criterion 2). Third, we  
325 tested if edges were present in secondary analyses using unregularized model search estimation,  
326 again confirmed in >50% of bootstrapped estimations exhibiting directionally consistent  
327 estimates (consistency criterion 3).



328 **Availability of data and materials**

329 Data from original studies is not openly available, but can be requested; see details in  
330 Supplementary Table 7. GWAS summary data for IL-6, IL-10, and TNF- $\alpha$  is openly available  
331 from the original publication by Ahola-Olli *and colleagues* (2017), for BMI from the GIANT  
332 consortium, and can be requested for CRP from the CHARGE inflammation working group. We  
333 provide analysis scripts and estimated network matrices (including bootstrapped network  
334 matrices) on the Open Science Platform (OSF) under <https://osf.io/q4vw9/>.

## 335 **RESULTS**

336 Baseline characteristics of study populations are displayed in Table 1.

337 -Table 1-

### 338 **Network analysis**

339 We conducted network analyses of five immuno-metabolic PRSs (CRP, IL-6, IL-10, TNF- $\alpha$ , &  
340 BMI) and seven depressive symptoms using two estimation techniques (FGL & unregularized  
341 model search estimation) in three samples (MARS, STAR\*D & UK Biobank). Bootstrap  
342 analyses were conducted to assess stability of networks and node predictability estimated using a  
343 mixed graphical model. We defined three consistency criteria to assess robustness and  
344 replicability of our results across estimation techniques, bootstrapping, and samples. Focus of this  
345 network investigation were unique associations (termed edges in network analysis) between PRSs  
346 and symptoms, which are summarised in Table 2.

#### 347 *Fused Graphical LASSO (FGL) estimation suggests four consistent PRS-symptom edges* 348 *according to criteria 1 & 2*

349 Using FGL estimation, we obtained networks that are visualised in Figure 2. PRS-symptom edge  
350 bootstrapping results are displayed in Figure 3 with PRS-PRS and symptom-symptom edge  
351 bootstrapping results shown in Supplementary Figures 4 and 5.

352 As expected, nodes within the same plane displayed relatively stronger within-plane (i.e.,  
353 symptom-symptom & PRS-PRS) than between-plane (i.e., PRS-symptom) associations. Among  
354 PRSs, CRP displayed associations with BMI (edge weight range across samples: 0.16-0.19) while  
355 IL-6, IL-10, and TNF- $\alpha$  (based on the same GWAS) were associated with each other (edge  
356 weight range across samples: 0.08-0.52). Associations of BMI and CRP with IL-6, IL-10, and  
357 TNF- $\alpha$  were largely absent or very small (edge weight range across samples: -0.02-0.01). Among

358 symptoms, the largest associations were present between the core symptoms depressed mood and  
359 anhedonia (edge weight range across samples: 0.14-0.55), which is to-be-expected in clinical  
360 samples where these symptoms form the basis of the MDD diagnosis. Supplementary Figure 4  
361 also illustrates interesting edge differences between samples that are likely arising from the  
362 diverging symptom definitions in individual samples. For instance, edges of fatigue with changes  
363 in appetite (edge weight=0.21) and sleep problems (edge weight=0.33) were relatively larger in  
364 the UK Biobank, assessing composite symptoms of changes in appetite and sleep problems, but  
365 substantially smaller in MARS (fatigue-changes in appetite: edge weight=0.09; fatigue-sleep  
366 problems: edge weight=0.10) and STAR\*D (fatigue-changes in appetite: edge weight=-0.01;  
367 fatigue-sleep problems: edge weight=-0.01), assessing loss of appetite and insomnia.

368 Regarding PRS-symptom edges, FGL estimation surprisingly resulted in a much larger number of  
369 PRS-symptom edges in MARS and STAR\*D samples compared to the UK Biobank sample with  
370 28 (MARS), 29 (STAR\*D), and 6 (UK Biobank) nonzero PRS-symptom edges. 26 (MARS), 28  
371 (STAR\*D), and 5 (UK Biobank) of these edges fulfilled criterion 1 (nonzero edges are nonzero  
372 and directionally consistent in >50% of bootstraps). Although the difference between samples  
373 could have resulted from network differences of clinical versus general population-based  
374 samples, it may also reflect some degree of inconsistency or even noise as edge estimates often  
375 exhibited unstable directions of association in clinical samples (see Table 2).

376 Applying consistency criterion 2 (consistency of results across samples), we observed replicable  
377 edges of the CRP PRS with anhedonia (negative edge weight), changes in appetite, and fatigue  
378 and of the TNF- $\alpha$  PRS with fatigue; these edges were manually unfaded in Figure 2. It is  
379 important to note that the edge between the CRP PRS and changes in appetite has a diverging  
380 valence in individual samples; in MARS and STAR\*D (assessing loss of appetite) the edge

381 weight was negative and in the UK Biobank study (assessing changes in appetite) the edge  
382 weight was positive.

383 -Figure 2-

384 -Figure 3-

385 ***Unregularized model search estimation suggests three consistent PRS-symptom edges***  
386 ***according to criterion 3.***

387 Using unregularized model search estimation, we again observed networks with relatively larger  
388 within-plane (i.e., PRS-PRS & symptom-symptom) than between-plane (i.e., PRS-symptom)  
389 edges. Networks were comparable to FGL estimation, but generally sparser than those using FGL  
390 estimation; see network graphs in Supplementary Figure 6 and bootstrapping results in  
391 Supplementary Figures 7-9.

392 Regarding PRS-symptom edges, only three edges were estimated, which were all observed in the  
393 UK Biobank sample and fulfilled consistency criterion 3 (nonzero edges are also nonzero and  
394 directionally consistent in >50% of bootstraps); these edges have been manually unfaded in  
395 Supplementary Figure 6. The specific PRS-symptom edges were between the BMI PRS and  
396 changes in appetite and anhedonia and between the CRP PRS and changes in appetite.

397 Comparing these edges to FGL estimation, the edge of the CRP PRS with changes in appetite  
398 replicated one of the edges fulfilling consistency criteria 1 and 2 while the two edges observed  
399 for the BMI PRS were only fulfilling consistency criterion 1 (presence in FGL estimation and  
400 >50% of bootstraps). Moreover, the BMI PRS association with anhedonia was negative using  
401 unregularized model search estimation, but positive using FGL estimation.

402 -Table 2-

403 *Node predictability*

404 Average node predictability was similar across samples for PRS nodes with 16% (UK Biobank),  
405 17% (MARS), and 19% (STAR\*D) of variance explained by all other nodes in the network.  
406 Contrary to this, average node predictability for symptom nodes differed with 38% of variance  
407 explained by all other nodes in the UK Biobank sample and only 9% in both clinical samples.  
408 These findings highlight differences in network density of symptoms in the UK Biobank (using  
409 the PHQ-9) and clinical samples (using the HAM-D).

## 410 **DISCUSSION**

411 The present study investigated associations of PRSs for immuno-metabolic markers with  
412 depressive symptoms using a multi-plane, multi-sample network analysis approach. Based on  
413 three consistency criteria emphasising robustness and replicability of network analysis results  
414 across statistical bootstraps, samples, and estimation methods, we observed a unique association  
415 between the CRP PRS and changes in appetite that met all three consistency criteria. In addition  
416 to this association, we observed five additional PRS-symptom associations that met two  
417 consistency criteria. These included edges of the CRP PRS with anhedonia (negative association)  
418 and fatigue, the TNF- $\alpha$  PRS with fatigue, and the BMI PRS with anhedonia and changes in  
419 appetite. However, the BMI PRS-anhedonia association switched association direction depending  
420 on the estimation method, so may not be fully consistent despite fulfilling our consistency  
421 criteria. Due to the novelty of our analysis approach, we highlight several methodological  
422 considerations below, which we hope provides a helpful framework to the discussion of our  
423 findings afterwards.

### 424 **Methodological challenges and opportunities**

425 Combining PRSs with psychological symptom networks is a relatively recent extension of  
426 network analysis and, to our knowledge, has only been applied in one previous investigation  
427 incorporating a schizophrenia PRS into a psychotic symptom network (Isvoranu et al., 2020).  
428 Therefore, it is important to emphasise the unique challenges and opportunities of this approach.  
429 First, as noted by Isvoranu *and colleagues* (2020), statistical power is potentially the greatest  
430 challenge of PRS-symptom network analysis. Network analysis itself requires relatively large  
431 sample sizes for psychological symptom networks (Epskamp et al., 2018; Fried and Cramer,  
432 2017), which should be in the hundreds or thousands depending on the number of nodes in the

433 network. Inclusion of PRSs into psychological symptom networks, and especially of potential  
434 pathomechanistic (e.g., inflammatory) rather than main illness (e.g., depression/schizophrenia)  
435 scores into these networks, aggravates the sample size requirements for network analysis as PRSs  
436 only explain a fraction of variance in the heritable component of their target phenotypes (Choi et  
437 al., 2020; Wray et al., 2020).

438 Second, and because PRSs only measure a fraction of variance in their target phenotype, unique  
439 associations observed in network analyses are inevitably smaller than actual target phenotype-  
440 symptom associations. Taking this study as an example, absolute sizes of CRP PRS-symptom  
441 associations were 5- to 10-fold smaller than those from a prior network investigation using serum  
442 CRP concentrations by Moriarity *and colleagues* (2020a). Therefore, PRS-symptom associations  
443 are unlikely to give meaningful insights into size of association with the target phenotype, but  
444 should, in our opinion, be interpreted based on robust presence/absence of specific associations.

445 Third, the large statistical power requirements and difficulty quantifying such power for a given  
446 study may lead to biased result interpretations. Absence of PRS-symptom associations could be  
447 interpreted as false negatives while presence of association may be interpreted as true positives.  
448 Such divergence in interpretation necessarily biases the literature towards hypothesis  
449 confirmation. Consequently, any associations observed in PRS-symptom network analyses  
450 should be followed up by- and interpreted in line with- evidence from other studies, thus adhering  
451 to the recommended triangulation of evidence approach (Lawlor et al., 2017; Ohlsson and  
452 Kendler, 2019).

453 Despite these challenges, PRS-symptom networks also provide multiple opportunities. First,  
454 PRSs reflect estimates of genetic liability to phenotype expression, so can give an indication on  
455 the influence of lifelong predisposition to higher phenotype levels on the symptom level. In this

456 way, PRS-symptom associations also provide an indication regarding temporality of association,  
457 which Bradford-Hill defined as one of the viewpoints for causality (Bradford Hill, 1965). It is  
458 important to note, however, that evidence for a unidirectional temporal association does not  
459 preclude bi-directionality. Moreover, PRSs combine information from a multitude of genetic  
460 variants (in our case from ~1 million SNPs) that are not restricted to functional SNPs, can include  
461 false positive associations (i.e., noise), and can also tag information of pleiotropic environmental  
462 confounding factors. Therefore, causal inferences should rely on separate evidence from clinical  
463 trials and/or more focused genetic approaches such as Mendelian Randomisation studies (Lawlor  
464 et al., 2008).

465 Second, the PRS-symptom network analysis approach allows the concurrent investigation of  
466 multiple immuno-metabolic markers with multiple symptoms. Thereby, immunological and  
467 clinical complexity is addressed concurrently, which is an advantage to previous investigations.  
468 Furthermore, network analyses usually estimate partial/unique associations, so any emerging  
469 associations could suggest direct causal paths from PRS phenotypes to individual symptoms, so  
470 may pinpoint so-called ‘bridge symptoms’ that act as etiological docking sites of risk effects on  
471 the symptom plane.

472 Third, large-scale population-based or patient cohort studies, commonly used in network  
473 analysis, often do not have detailed immunophenotyping data available. If at all, studies mostly  
474 have data available for serum CRP, but rarely for more specific cytokines. Conversely, the advent  
475 of large GWAS investigations has produced a substantial amount of large cohort databases with  
476 in-depth genotyping and phenotyping information. Combining such databases with GWAS  
477 summary statistics from more focused investigations, such as on individual cytokines (Ahola-Olli



478 et al., 2017), enables the investigation of a diverse range of immunopsychiatric research  
479 questions.

480 Fourth, PRS-symptom networks could be extended, for instance, by adding serum inflammatory  
481 markers to these networks, which could provide additional insights into associations between  
482 genetic/lifelong predisposition to, and acute levels of, immuno-metabolic markers with individual  
483 symptoms.

#### 484 **Associations of immuno-metabolic markers with depressive symptoms**

485 Network analysis results showed consistent associations of the CRP PRS with changes in  
486 appetite, which was the only association that fulfilled all of our quality criteria. The BMI PRS  
487 showed similar associations with changes in appetite, but only fulfilled two quality criteria.  
488 Importantly, both of these associations were positive in the UK Biobank sample, which assessed  
489 changes in appetite, and negative in MARS and STAR\*D samples, which assessed loss of  
490 appetite. Previous studies reporting results from cross-sectional, longitudinal, genetic correlation,  
491 PRS, and Mendelian randomisation analyses have also consistently reported associations of  
492 CRP/BMI with changes in appetite (Fried et al., 2019; Jokela et al., 2016; Kappelmann et al.,  
493 2021; Moriarity et al., 2020a). Importantly, whenever studies disaggregated appetite symptoms  
494 into decreased versus increased appetite, associations of CRP/BMI were specific to increased  
495 appetite (Lamers et al., 2018; Milaneschi et al., 2021b, 2021a, 2017b; Pistis et al., 2021;  
496 Simmons et al., 2018). In light of these findings, our results provide indirect support for an  
497 immune-metabolic contribution to increased appetite specifically.

498 In addition to these PRS associations with changes in appetite, we also observed associations of  
499 higher CRP PRS with lower anhedonia and greater fatigue and of higher TNF- $\alpha$  PRS with greater  
500 fatigue. Fatigue in particular has long been considered to have a neuroimmune basis (Dantzer et

501 al., 2014), is common across other medical illnesses characterised by chronic inflammation, and  
502 has been reliably associated with inflammatory markers in previous studies including two  
503 network investigations (Fried et al., 2019; Jokela et al., 2016; Lamers et al., 2020; Moriarity et  
504 al., 2020a; van Eeden et al., 2020; White et al., 2017). While there have also been some studies  
505 suggesting associations of inflammatory markers with anhedonia (Köhler-Forsberg et al., 2017;  
506 van Eeden et al., 2020), it is important to note that associations of the CRP PRS with anhedonia  
507 observed in the present report were negative, so do not offer straightforward replication of these  
508 findings. Nonetheless, we have recently shown in Mendelian randomisation analyses that BMI  
509 could be a potential causal factor for both fatigue and anhedonia (Kappelmann et al., 2021), so  
510 continued investigation of these symptoms is warranted.

511 Together, our findings add to the notion of an immuno-metabolic subtype of depression  
512 characterised by neurovegetative symptoms of changes in appetite and fatigue (Dantzer et al.,  
513 2008; Milaneschi et al., 2020). We also expand upon previous work by showing that  
514 genetic/lifetime predisposition to higher inflammation and metabolic dysregulation increases risk  
515 for depression and, based on network analysis results, these etiological factors may specifically  
516 confer their risk on the broader depression syndrome through symptoms such as changes in  
517 appetite and fatigue. These results can inform the design of clinical trials of anti-inflammatory  
518 approaches and metabolic interventions by specifically selecting patients with an atypical,  
519 neurovegetative symptom presentation. As clinical trials for immune-modulating drugs are  
520 currently still characterised by relatively small sample sizes (Husain et al., 2020; Khandaker et  
521 al., 2018; McIntyre et al., 2019; Nettis et al., 2021; Raison et al., 2013), it may be worthwhile to  
522 pilot new interventions with neurovegetative symptoms/phenotypes as outcome variables. This  
523 might increase statistical power and sensitivity to detect effects for these proof-of-concept trials  
524 and could then be followed up by larger trials testing broader clinical efficacy measures.

525 **Strengths and limitations**

526 Strength of this study include availability of large general population-based and patient samples  
527 (maximising replicability and generalisability), polygenic definition of immuno-metabolic risk  
528 variables (indexing lifetime predisposition to higher immuno-metabolic marker levels), and  
529 application of network analysis (addressing immunological and clinical complexity  
530 concurrently). We have addressed some of the more general limitations of combined PRS-  
531 symptom network analysis above, but there are three more specific limitations that warrant  
532 mentioning.

533 First, data used in the current study included inpatients, outpatients, and individuals from the  
534 general population and was based on different scales to measure depressive symptoms.

535 Depressive symptom structure varies between acutely ill patients versus those in remission (van  
536 Borkulo et al., 2015), which may have influenced PRS-symptom associations. Moreover, two of  
537 the seven symptoms used in the present report only overlap partially; the UK Biobank study  
538 includes conflated items on sleep problems and changes in appetite while MARS and STAR\*D  
539 include items on insomnia and loss of appetite, respectively. This difference may explain some of  
540 the inconsistencies observed in the current report such as the diverging valence of edge estimates  
541 between CRP and changes in appetite. However, this may have also reduced statistical power to  
542 detect associations. Study questionnaires also differed regarding the method of assessment as the  
543 HAM-D is observer-rated and the PHQ-9 self-reported. By definition, inflammation-symptom  
544 research is affected from modality-specific measurement variability (Moriarty and Alloy, 2021)  
545 and in our study this is aggravated through the added variability unique to the method of  
546 symptom assessment (Möller, 2000). Future studies would benefit from inclusion of studies with  
547 the same questionnaire and disaggregated symptom measures.

548 Second, the combination of clinical and general population samples poses unique challenges. The  
549 application of a clinical depression measure in the UK Biobank study could have resulted in  
550 potential floor effects for some symptoms while specific selection of MDD patients into MARS  
551 and STAR\*D studies could have resulted in ceiling effects for core symptoms of depressed mood  
552 and anhedonia as these are required for a diagnosis. Selection of clinical populations in network  
553 studies can also result in Berkson/collider bias (de Ron et al., 2019), which can induce negative  
554 correlations. This again warrants replication of our results in independent samples.

555 Third, PRSs are based on GWAS with highly diverging samples sizes as a large number of  
556 individuals were included in the GWAS for BMI and CRP (>200 thousand individuals) and  
557 smaller numbers of individuals (~8 thousand individuals) for IL-6, IL-10, and TNF- $\alpha$ .  
558 Consistency of effect sizes following the PRS-CS approach was also larger for CRP and BMI as  
559 compared to IL-6, IL-10, and TNF- $\alpha$ . This is likely to have shifted the balance of statistical  
560 power towards detection of PRS-symptom associations to BMI and CRP rather than IL-6, IL-10,  
561 and TNF- $\alpha$ . Therefore, our findings require replication once larger individual cytokine GWAS  
562 become available.

## 563 **Conclusion**

564 The present investigation studied associations between four major pro- and anti-inflammatory  
565 markers, BMI, and depressive symptoms by applying network analysis across one large general  
566 population and two patient samples. Defining immuno-metabolic markers using polygenic risk  
567 scores expanded previous reports by suggesting direct associations of genetic/lifetime  
568 predisposition to immune-metabolic markers with depressive symptoms and provided evidence  
569 for temporality of association. Despite methodological restrictions of the presented approach, we  
570 observed associations of polygenic risk for CRP with changes in appetite and fatigue, for TNF- $\alpha$

571 with fatigue, and similar associations for BMI. These findings align with recent  
572 conceptualisations of an immuno-metabolic subgroup of depressed patients characterised by  
573 atypical, neurovegetative symptom profiles. Results can inform future clinical trials of anti-  
574 inflammatory approaches by prioritising these patients for selection into clinical trials.

## **DECLARATION OF INTERESTS**

The authors do not have any competing interests.

## **FUNDING**

This study is funded by the Max Planck Institute of Psychiatry. NK, NR, and SM are supported by the International Max Planck Research School of Translational Psychiatry (IMPRS-TP). NR received funding from the Bavarian Ministry of Economic Affairs, Regional Development and Energy (BayMED, PBN\_MED-1711-0003). GMK acknowledges funding support from the Wellcome Trust (grant code: 201486/Z/16/Z), the MQ: Transforming Mental Health (grant code: MQDS17/40), the Medical Research Council, UK (grant code: MC\_PC\_17213 and grant code: MR/S037675/1), and the BMA Foundation (J Moulton grant 2019). JA received support by a NARSAD Young Investigator Grant from Brain and Behavior Research Foundation.

## **ACKNOWLEDGMENTS**

We are grateful to all original authors, technical assistants and patients who contributed to the MARS study. We are grateful for the National Institute of Mental Health (NIMH) and the NIMH Repository and Genomics Resource (NRGR) for the possibility of analysing the STAR\*D data. We are also grateful to the original STAR\*D authors, and particularly for the contributions of all patients and families who participated in the study. Data were obtained from the limited access datasets distributed from the NIH-supported ‘Sequenced Treatment Alternatives to Relieve Depression’ (STAR\*D). The study was supported by NIMH Contract No. N01MH90003 to the University of Texas Southwestern Medical Center. The ClinicalTrials.gov identifier is NCT00021528. This research has been conducted using the UK Biobank Resource. We are grateful for all scientists and participants who made this large-scale effort and resource possible.

## REFERENCES

- Ahola-Olli, A. V, Würtz, P., Havulinna, A.S., Aalto, K., Pitkänen, N., Lehtimäki, T., Kähönen, M., Lyytikäinen, L.-P., Raitoharju, E., Seppälä, I., Sarin, A.-P., Ripatti, S., Jalkanen, S., Maksimow, M., Salomaa, V., Salmi, M., Kettunen, J., Raitakari, O.T., 2017. Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors. *Am. J. Hum. Genet.* 100, 40–50.  
<https://doi.org/10.1016/j.ajhg.2016.11.007>
- Badini, I., Coleman, J.R., Hagenaars, S.P., Hotopf, M., Breen, G., Lewis, C.M., Fabbri, C., 2020. Depression with atypical neurovegetative symptoms shares genetic predisposition with immuno-metabolic traits and alcohol consumption. *Psychol. Med.* 1–11.  
<https://doi.org/10.1017/S0033291720002342>
- Bilder, R.M., Volavka, J., Lachman, H.M., Grace, A.A., 2004. The Catechol-O-Methyltransferase Polymorphism: Relations to the Tonic–Phasic Dopamine Hypothesis and Neuropsychiatric Phenotypes. *Neuropsychopharmacology* 29, 1943–1961.  
<https://doi.org/10.1038/sj.npp.1300542>
- Borsboom, D., 2017. A network theory of mental disorders. *World Psychiatry* 16, 5–13.  
<https://doi.org/10.1002/wps.20375>
- Bradford Hill, A., 1965. The environment and disease: association or causation? *Proc. R. Soc. Med.* 58, 295.
- Bycroft, C., Freeman, C., Petkova, D., Band, G., Elliott, L.T., Sharp, K., Motyer, A., Vukcevic, D., Delaneau, O., O’Connell, J., Cortes, A., Welsh, S., Young, A., Effingham, M., McVean, G., Leslie, S., Allen, N., Donnelly, P., Marchini, J., 2018. The UK Biobank resource with

deep phenotyping and genomic data. *Nature* 562, 203–209. <https://doi.org/10.1038/s41586-018-0579-z>

Cattaneo, A., Ferrari, C., Turner, L., Mariani, N., Enache, D., Hastings, C., Kose, M., Lombardo, G., McLaughlin, A.P., Nettis, M.A., Nikkheslat, N., Sforzini, L., Worrell, C., Zajkowska, Z., Cattane, N., Lopizzo, N., Mazzelli, M., Pointon, L., Cowen, P.J., Cavanagh, J., Harrison, N.A., de Boer, P., Jones, D., Drevets, W.C., Mondelli, V., Bullmore, E.T., Pariante, C.M., 2020. Whole-blood expression of inflammasome- and glucocorticoid-related mRNAs correctly separates treatment-resistant depressed patients from drug-free and responsive patients in the BIODep study. *Transl. Psychiatry* 10, 232. <https://doi.org/10.1038/s41398-020-00874-7>

Choi, S.W., Mak, T.S.-H., O'Reilly, P.F., 2020. Tutorial: a guide to performing polygenic risk score analyses. *Nat. Protoc.* 15, 2759–2772. <https://doi.org/10.1038/s41596-020-0353-1>

Chu, A.L., Stochl, J., Lewis, G., Zammit, S., Jones, P.B., Khandaker, G.M., 2019. Longitudinal association between inflammatory markers and specific symptoms of depression in a prospective birth cohort. *Brain. Behav. Immun.* 76, 74–81. <https://doi.org/10.1016/j.bbi.2018.11.007>

Contreras, A., Nieto, I., Valiente, C., Espinosa, R., Vazquez, C., 2019. The Study of Psychopathology from the Network Analysis Perspective: A Systematic Review. *Psychother. Psychosom.* 88, 71–83. <https://doi.org/10.1159/000497425>

Costantini, G., Kappelmann, N., Epskamp, S., 2020. EstimateGroupNetwork: Perform the Joint Graphical Lasso and Selects Tuning Parameters.

Costantini, G., Richetin, J., Preti, E., Casini, E., Epskamp, S., Perugini, M., 2019. Stability and



- variability of personality networks. A tutorial on recent developments in network psychometrics. *Pers. Individ. Dif.* 136, 68–78. <https://doi.org/10.1016/j.paid.2017.06.011>
- Danaher, P., Wang, P., Witten, D.M., 2014. The joint graphical lasso for inverse covariance estimation across multiple classes. *J. R. Stat. Soc. Ser. B (Statistical Methodol.* 76, 373–397. <https://doi.org/10.1111/rssb.12033>
- Dantzer, R., Heijnen, C.J., Kavelaars, A., Laye, S., Capuron, L., 2014. The neuroimmune basis of fatigue. *Trends Neurosci.* 37, 39–46. <https://doi.org/10.1016/j.tins.2013.10.003>
- Dantzer, R., O'Connor, J.C., Freund, G.G., Johnson, R.W., Kelley, K.W., 2008. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat. Rev. Neurosci.* 9, 46–56. <https://doi.org/10.1038/nrn2297>
- Davis, K.A.S., Coleman, J.R.I., Adams, M., Allen, N., Breen, G., Cullen, B., Dickens, C., Fox, E., Graham, N., Holliday, J., Howard, L.M., John, A., Lee, W., McCabe, R., McIntosh, A., Pearsall, R., Smith, D.J., Sudlow, C., Ward, J., Zammit, S., Hotopf, M., 2020. Mental health in UK Biobank – development, implementation and results from an online questionnaire completed by 157 366 participants: a reanalysis. *BJPsych Open* 6, e18. <https://doi.org/10.1192/bjo.2019.100>
- de Ron, J., Fried, E.I., Epskamp, S., 2019. Psychological networks in clinical populations: investigating the consequences of Berkson's bias. *Psychol. Med.* 1–9. <https://doi.org/10.1017/S0033291719003209>
- Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E.K., Lanctôt, K.L., 2010. A Meta-Analysis of Cytokines in Major Depression. *Biol. Psychiatry* 67, 446–457. <https://doi.org/10.1016/j.biopsych.2009.09.033>

Epskamp, S., Borsboom, D., Fried, E.I., 2018. Estimating psychological networks and their accuracy: A tutorial paper. *Behav. Res. Methods* 50, 195–212.

<https://doi.org/10.3758/s13428-017-0862-1>

Epskamp, S., Cramer, A.O.J., Waldorp, L.J., Schmittmann, V.D., Borsboom, D., 2012. qgraph: Network Visualizations of Relationships in Psychometric Data. *J. Stat. Softw.* 48, 1–18.

<https://doi.org/10.18637/jss.v048.i04>

Fried, E.I., Cramer, A.O.J., 2017. Moving forward: Challenges and direction for psychopathological network theory and methodology. *Perspect. Psychol. Sci.* 12, 999–1020.

<https://doi.org/10.1177/1745691617705892>

Fried, E.I., von Stockert, S., Haslbeck, J.M.B., Lamers, F., Schoevers, R.A., Penninx, B.W.J.H., 2019. Using network analysis to examine links between individual depressive symptoms, inflammatory markers, and covariates. *Psychol. Med.* 1–9.

<https://doi.org/10.1017/S0033291719002770>

Garriock, H.A., Kraft, J.B., Shyn, S.I., Peters, E.J., Yokoyama, J.S., Jenkins, G.D., Reinalda, M.S., Slager, S.L., McGrath, P.J., Hamilton, S.P., 2010. A Genomewide Association Study of Citalopram Response in Major Depressive Disorder. *Biol. Psychiatry* 67, 133–138.

<https://doi.org/10.1016/j.biopsych.2009.08.029>

Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C.A., Smoller, J.W., 2019. Polygenic prediction via Bayesian regression and continuous shrinkage priors. *Nat. Commun.* 10, 1776.

<https://doi.org/10.1038/s41467-019-09718-5>

Goldsmith, D.R., Rapaport, M.H., Miller, B.J., 2016. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and

depression. *Mol. Psychiatry* 21, 1696–1709. <https://doi.org/10.1038/mp.2016.3>

Guloksuz, S., Pries, L.-K., van Os, J., 2017. Application of network methods for understanding mental disorders: pitfalls and promise. *Psychol. Med.* 47, 2743–2752.

<https://doi.org/10.1017/S0033291717001350>

Haapakoski, R., Mathieu, J., Ebmeier, K.P., Alenius, H., Kivimäki, M., 2015. Cumulative meta-analysis of interleukins 6 and 1 $\beta$ , tumour necrosis factor  $\alpha$  and C-reactive protein in patients with major depressive disorder. *Brain. Behav. Immun.* 49, 206–215.

<https://doi.org/10.1016/j.bbi.2015.06.001>

Hamilton, M., 1986. The Hamilton Rating Scale for Depression, in: Sartorius, N., Ban, T.A. (Eds.), *Assessment of Depression*. Springer Berlin Heidelberg, Berlin, Heidelberg, pp. 143–152. [https://doi.org/10.1007/978-3-642-70486-4\\_14](https://doi.org/10.1007/978-3-642-70486-4_14)

Haslbeck, J.M.B., Fried, E.I., 2017. How predictable are symptoms in psychopathological networks? A reanalysis of 18 published datasets. *Psychol. Med.* 47, 2767–2776.

<https://doi.org/10.1017/S0033291717001258>

Haslbeck, J.M.B., Waldorp, L.J., 2020.  $\text{mgm}^2$ : Estimating Time-Varying Mixed Graphical Models in High-Dimensional Data. *J. Stat. Softw.* 93. <https://doi.org/10.18637/jss.v093.i08>

Hennings, J.M., Owashi, T., Binder, E.B., Horstmann, S., Menke, A., Kloiber, S., Dose, T., Wollweber, B., Spieler, D., Messer, T., Lutz, R., Kü Nzel, H., Bierner, T., Pollmächer, T., Pfister, H., Nickel, T., Sonntag, A., Uhr, M., Ising, M., Holsboer, F., Lucae, S., 2009. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients – Findings from the Munich Antidepressant Response Signature (MARS) project. *J. Psychiatr. Res.* 43, 215–229. <https://doi.org/10.1016/j.jpsychires.2008.05.002>

- Howren, M.B., Lamkin, D.M., Suls, J., 2009. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. *Psychosom. Med.* 71, 171–186.  
<https://doi.org/10.1097/PSY.0b013e3181907c1b>
- Husain, M.I., Chaudhry, I.B., Khoso, A.B., Husain, M.O., Hodsoll, J., Ansari, M.A., Naqvi, H.A., Minhas, F.A., Carvalho, A.F., Meyer, J.H., Deakin, B., Mulsant, B.H., Husain, N., Young, A.H., 2020. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial. *The Lancet Psychiatry* 7, 515–527.  
[https://doi.org/10.1016/S2215-0366\(20\)30138-3](https://doi.org/10.1016/S2215-0366(20)30138-3)
- Isvoranu, A.-M., Guloksuz, S., Epskamp, S., van Os, J., Borsboom, D., 2020. Toward incorporating genetic risk scores into symptom networks of psychosis. *Psychol. Med.* 50, 636–643. <https://doi.org/10.1017/S003329171900045X>
- Jokela, M., Virtanen, M., Batty, G., Kivimäki, M., 2016. Inflammation and specific symptoms of depression. *JAMA Psychiatry* 73, 87–88. <https://doi.org/10.1001/jamapsychiatry.2015.1977>
- Kappelmann, N., Arloth, J., Georgakis, M.K., Czamara, D., Rost, N., Ligthart, S., Khandaker, G.M., Binder, E.B., 2021. Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms. *JAMA Psychiatry* 78, 161–170.  
<https://doi.org/10.1001/jamapsychiatry.2020.3436>
- Kappelmann, N., Lewis, G., Dantzer, R., Jones, P.B., Khandaker, G.M., 2018. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. *Mol. Psychiatry* 23, 335–343.  
<https://doi.org/10.1038/mp.2016.167>
- Khandaker, G.M., Oltean, B.P., Kaser, M., Dibben, C.R.M., Ramana, R., Jadon, D.R., Dantzer,

- R., Coles, A.J., Lewis, G., Jones, P.B., 2018. Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. *BMJ Open* 8, e025333. <https://doi.org/10.1136/bmjopen-2018-025333>
- Khandaker, G.M., Pearson, R.M., Zammit, S., Lewis, G., Jones, P.B., 2014. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. *JAMA Psychiatry* 71, 1121–1128. <https://doi.org/10.1001/jamapsychiatry.2014.1332>
- Köhler-Forsberg, O., Buttenschøn, H.N., Tansey, K.E., Maier, W., Hauser, J., Dernovsek, M.Z., Henigsberg, N., Souery, D., Farmer, A., Rietschel, M., McGuffin, P., Aitchison, K.J., Uher, R., Mors, O., 2017. Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. *Brain. Behav. Immun.* 62, 344–350. <https://doi.org/10.1016/j.bbi.2017.02.020>
- Köhler-Forsberg, O., Nicolaisen Lydholm, C., Hjorthøj, C., Nordentoft, M., Mors, O., Benros, M.E., 2019. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: Meta-analysis of clinical trials. *Acta Psychiatr. Scand.* 0–2. <https://doi.org/10.1111/acps.13016>
- Köhler, C.A., Freitas, T.H., Maes, M., de Andrade, N.Q., Liu, C.S., Fernandes, B.S., Stubbs, B., Solmi, M., Veronese, N., Herrmann, N., Raison, C.L., Miller, B.J., Lanctôt, K.L., Carvalho, A.F., 2017. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. *Acta Psychiatr. Scand.* 135, 373–387. <https://doi.org/10.1111/acps.12698>
- Lamers, F., Milaneschi, Y., de Jonge, P., Giltay, E.J., Penninx, B.W.J.H., 2018. Metabolic and inflammatory markers: associations with individual depressive symptoms. *Psychol. Med.* 48,

1102–1110. <https://doi.org/10.1017/S0033291717002483>

Lamers, F., Milaneschi, Y., Smit, J.H., Schoevers, R.A., Wittenberg, G., Penninx, B.W.J.H.,  
2019. Longitudinal Association Between Depression and Inflammatory Markers: Results  
From the Netherlands Study of Depression and Anxiety. *Biol. Psychiatry* 85, 829–837.  
<https://doi.org/10.1016/j.biopsych.2018.12.020>

Lamers, F., Milaneschi, Y., Vinkers, C.H., Schoevers, R.A., Giltay, E.J., Penninx, B.W.J.H.,  
2020. Depression profilers and immuno-metabolic dysregulation: Longitudinal results from  
the NESDA study. *Brain. Behav. Immun.* 88, 174–183.  
<https://doi.org/10.1016/j.bbi.2020.04.002>

Lamnidis, T.C., Majander, K., Jeong, C., Salmela, E., Wessman, A., Moiseyev, V., Khartanovich,  
V., Balanovsky, O., Ongyerth, M., Weihmann, A., Sajantila, A., Kelso, J., Pääbo, S.,  
Onkamo, P., Haak, W., Krause, J., Schiffels, S., 2018. Ancient Fennoscandian genomes  
reveal origin and spread of Siberian ancestry in Europe. *Nat. Commun.* 9, 5018.  
<https://doi.org/10.1038/s41467-018-07483-5>

Lawlor, D.A., Harbord, R.M., Sterne, J.A.C., Timpson, N., Davey Smith, G., 2008. Mendelian  
randomization: Using genes as instruments for making causal inferences in epidemiology.  
*Stat. Med.* 27, 1133–1163. <https://doi.org/10.1002/sim.3034>

Lawlor, D.A., Tilling, K., Davey Smith, G., 2017. Triangulation in aetiological epidemiology.  
*Int. J. Epidemiol.* 45, dyw314. <https://doi.org/10.1093/ije/dyw314>

Ligthart, S., Vaez, A., Vösa, U., Stathopoulou, M.G., de Vries, P.S., Prins, B.P., Van der Most,  
P.J., Tanaka, T., Naderi, E., Rose, L.M., Wu, Y., Karlsson, R., Barbalic, M., Lin, H., Pool,  
R., Zhu, G., Macé, A., Sidore, C., Trompet, S., Mangino, M., Sabater-Lleal, M., Kemp, J.P.,

Abbasi, A., Kacprowski, T., Verweij, N., Smith, A. V, Huang, T., Marzi, C., Feitosa, M.F., Lohman, K.K., Kleber, M.E., Milaneschi, Y., Mueller, C., Huq, M., Vlachopoulou, E., Lyytikäinen, L.-P., Oldmeadow, C., Deelen, J., Perola, M., Zhao, J.H., Feenstra, B., Amini, M., Lahti, J., Schraut, K.E., Fornage, M., Suktitipat, B., Chen, W.-M., Li, X., Nutile, T., Malerba, G., Luan, J., Bak, T., Schork, N., Del Greco M., F., Thiering, E., Mahajan, A., Marioni, R.E., Mihailov, E., Eriksson, Joel, Ozel, A.B., Zhang, W., Nethander, M., Cheng, Y.-C., Aslibekyan, S., Ang, W., Gandin, I., Yengo, L., Portas, L., Kooperberg, C., Hofer, E., Rajan, K.B., Schurmann, C., den Hollander, W., Ahluwalia, Tarunveer S., Zhao, J., Draisma, H.H.M., Ford, I., Timpson, N., Teumer, A., Huang, H., Wahl, S., Liu, Y., Huang, J., Uh, H.-W., Geller, F., Joshi, P.K., Yanek, L.R., Trabetti, E., Lehne, B., Vozzi, D., Verbanck, M., Biino, G., Saba, Y., Meulenbelt, I., O’Connell, J.R., Laakso, M., Giulianini, F., Magnusson, P.K.E., Ballantyne, C.M., Hottenga, J.J., Montgomery, G.W., Rivadineira, F., Rueedi, R., Steri, M., Herzig, K.-H., Stott, D.J., Menni, C., Frånberg, M., St. Pourcain, B., Felix, S.B., Pers, T.H., Bakker, S.J.L., Kraft, P., Peters, A., Vaidya, D., Delgado, G., Smit, J.H., Großmann, V., Sinisalo, J., Seppälä, I., Williams, S.R., Holliday, E.G., Moed, M., Langenberg, C., Rääkkönen, K., Ding, J., Campbell, H., Sale, M.M., Chen, Y.-D.I., James, A.L., Ruggiero, D., Soranzo, N., Hartman, C.A., Smith, E.N., Berenson, G.S., Fuchsberger, C., Hernandez, D., Tiesler, C.M.T., Giedraitis, V., Liewald, D., Fischer, K., Mellström, D., Larsson, A., Wang, Y., Scott, W.R., Lorentzon, M., Beilby, J., Ryan, K.A., Pennell, C.E., Vuckovic, D., Balkau, B., Concas, M.P., Schmidt, R., Mendes de Leon, C.F., Bottinger, E.P., Kloppenburg, M., Paternoster, L., Boehnke, M., Musk, A.W., Willemsen, G., Evans, D.M., Madden, P.A.F., Kähönen, M., Kutalik, Z., Zoledziewska, M., Karhunen, V., Kritchevsky, S.B., Sattar, N., Lachance, G., Clarke, R., Harris, T.B., Raitakari, O.T., Attia, J.R., van Heemst, D., Kajantie, E., Sorice, R., Gambaro, G., Scott, R.A., Hicks, A.A.,

Ferrucci, L., Standl, M., Lindgren, C.M., Starr, J.M., Karlsson, M., Lind, L., Li, J.Z., Chambers, J.C., Mori, T.A., de Geus, E.J.C.N., Heath, A.C., Martin, N.G., Auvinen, J., Buckley, B.M., de Craen, A.J.M., Waldenberger, M., Strauch, K., Meitinger, T., Scott, R.J., McEvoy, M., Beekman, M., Bombieri, C., Ridker, P.M., Mohlke, K.L., Pedersen, N.L., Morrison, A.C., Boomsma, D.I., Whitfield, J.B., Strachan, D.P., Hofman, A., Vollenweider, P., Cucca, F., Jarvelin, M.-R., Jukema, J.W., Spector, T.D., Hamsten, A., Zeller, T., Uitterlinden, André G., Nauck, M., Gudnason, V., Qi, L., Grallert, H., Borecki, I.B., Rotter, J.I., März, W., Wild, P.S., Lokki, M.-L., Boyle, M., Salomaa, V., Melbye, M., Eriksson, J.G., Wilson, J.F., Penninx, B.W.J.H., Becker, D.M., Worrall, B.B., Gibson, G., Krauss, R.M., Ciullo, M., Zaza, G., Wareham, N.J., Oldehinkel, A.J., Palmer, L.J., Murray, S.S., Pramstaller, P.P., Bandinelli, S., Heinrich, J., Ingelsson, E., Deary, I.J., Mägi, R., Vandenput, L., van der Harst, P., Desch, K.C., Kooner, J.S., Ohlsson, C., Hayward, C., Lehtimäki, T., Shuldiner, A.R., Arnett, D.K., Beilin, L.J., Robino, A., Froguel, P., Pirastu, M., Jess, T., Koenig, W., Loos, R.J.F., Evans, D.A., Schmidt, H., Davey Smith, G., Slagboom, P.E., Eiriksdottir, G., Morris, A.P., Psaty, B.M., Tracy, R.P., Nolte, I.M., Boerwinkle, E., Visvikis-Siest, S., Reiner, A.P., Gross, M., Bis, J.C., Franke, L., Franco, O.H., Benjamin, E.J., Chasman, D.I., Dupuis, Josée, Snieder, H., Dehghan, A., Alizadeh, B.Z., Alizadeh, B.Z., Boezen, H.M., Franke, L., van der Harst, P., Navis, G., Rots, M., Snieder, H., Swertz, M., Wolfenbittel, B.H.R., Wijmenga, C., Benjamin, E., Chasman, D.I., Dehghan, A., Ahluwalia, Tarunveer Singh, Meigs, J., Tracy, R., Alizadeh, B.Z., Ligthart, S., Bis, J., Eiriksdottir, G., Pankratz, N., Gross, M., Rainer, A., Snieder, H., Wilson, J.G., Psaty, B.M., Dupuis, Josee, Prins, B., Vaso, U., Stathopoulou, M., Franke, L., Lehtimäki, T., Koenig, W., Jamshidi, Y., Siest, S., Abbasi, A., Uitterlinden, Andre G., Abdollahi, M., Schnabel, R., Schick, U.M., Nolte, I.M., Kraja, A., Hsu, Y.-H., Tylee, D.S.,



- Zwicker, A., Uher, R., Davey Smith, G., Morrison, A.C., Hicks, A., van Duijn, C.M., Ward-Caviness, C., Boerwinkle, E., Rotter, J., Rice, K., Lange, L., Perola, M., de Geus, E., Morris, A.P., Makela, K.M., Stacey, D., Eriksson, Johan, Frayling, T.M., Slagboom, E.P., 2018. Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders. *Am. J. Hum. Genet.* 103, 691–706. <https://doi.org/10.1016/j.ajhg.2018.09.009>
- Liu, J.J., Wei, Y. Bin, Strawbridge, R., Bao, Y., Chang, S., Shi, L., Que, J., Gadad, B.S., Trivedi, M.H., Kelsoe, J.R., Lu, L., 2020. Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis. *Mol. Psychiatry* 25, 339–350. <https://doi.org/10.1038/s41380-019-0474-5>
- Locke, A.E., Kahali, B., Berndt, S.I., Justice, A.E., Pers, T.H., Day, F.R., Powell, C., Vedantam, S., Buchkovich, M.L., Yang, J., Croteau-Chonka, D.C., Esko, T., Fall, T., Ferreira, T., Gustafsson, S., Kutalik, Z., Luan, J., Mägi, R., Randall, J.C., Winkler, T.W., Wood, A.R., Workalemahu, T., Faul, J.D., Smith, J.A., Hua Zhao, J., Zhao, W., Chen, J., Fehrmann, R., Hedman, Å.K., Karjalainen, J., Schmidt, E.M., Absher, D., Amin, N., Anderson, D., Beekman, M., Bolton, J.L., Bragg-Gresham, J.L., Buyske, S., Demirkan, A., Deng, G., Ehret, G.B., Feenstra, B., Feitosa, M.F., Fischer, K., Goel, A., Gong, J., Jackson, A.U., Kanoni, S., Kleber, M.E., Kristiansson, K., Lim, U., Lotay, V., Mangino, M., Mateo Leach, I., Medina-Gomez, C., Medland, S.E., Nalls, M.A., Palmer, C.D., Pasko, D., Pechlivanis, S., Peters, M.J., Prokopenko, I., Shungin, D., Stančáková, A., Strawbridge, R.J., Ju Sung, Y., Tanaka, Toshiko, Teumer, A., Trompet, S., van der Laan, S.W., van Setten, J., Van Vliet-Ostaptchouk, J. V., Wang, Z., Yengo, L., Zhang, W., Isaacs, A., Albrecht, E., Ärnlöv, J., Arscott, G.M., Attwood, A.P., Bandinelli, S., Barrett, A., Bas, I.N., Bellis, C., Bennett, A.J.,

Berne, C., Blagieva, R., Blüher, M., Böhringer, S., Bonnycastle, L.L., Böttcher, Y., Boyd, H.A., Bruinenberg, M., Caspersen, I.H., Ida Chen, Y.-D., Clarke, R., Warwick Daw, E., de Craen, A.J.M., Delgado, G., Dimitriou, M., Doney, A.S.F., Eklund, N., Estrada, K., Eury, E., Folkersen, L., Fraser, R.M., Garcia, M.E., Geller, F., Giedraitis, V., Gigante, B., Go, A.S., Golay, A., Goodall, A.H., Gordon, S.D., Gorski, M., Grabe, H.-J., Grallert, H., Grammer, T.B., Gräßler, J., Grönberg, H., Groves, C.J., Gusto, G., Haessler, J., Hall, P., Haller, T., Hallmans, G., Hartman, C.A., Hassinen, M., Hayward, C., Heard-Costa, N.L., Helmer, Q., Hengstenberg, C., Holmen, O., Hottenga, J.-J., James, A.L., Jeff, J.M., Johansson, Å., Jolley, J., Juliusdottir, T., Kinnunen, L., Koenig, W., Koskenvuo, M., Kratzer, W., Laitinen, J., Lamina, C., Leander, K., Lee, N.R., Lichtner, P., Lind, L., Lindström, J., Sin Lo, K., Lobbens, S., Lorbeer, R., Lu, Y., Mach, F., Magnusson, P.K.E., Mahajan, A., McArdle, W.L., McLachlan, S., Menni, C., Merger, S., Mihailov, E., Milani, L., Moayyeri, A., Monda, K.L., Morken, M.A., Mulas, A., Müller, G., Müller-Nurasyid, M., Musk, A.W., Nagaraja, R., Nöthen, M.M., Nolte, I.M., Pilz, S., Rayner, N.W., Renstrom, F., Rettig, R., Ried, J.S., Ripke, S., Robertson, N.R., Rose, L.M., Sanna, S., Scharnagl, H., Scholtens, S., Schumacher, F.R., Scott, W.R., Seufferlein, T., Shi, J., Vernon Smith, A., Smolonska, J., Stanton, A. V., Steinthorsdottir, V., Stirrups, K., Stringham, H.M., Sundström, J., Swertz, M.A., Swift, A.J., Syvänen, A.-C., Tan, S.-T., Tayo, B.O., Thorand, B., Thorleifsson, G., Tyrer, J.P., Uh, H.-W., Vandenput, L., Verhulst, F.C., Vermeulen, S.H., Verweij, N., Vonk, J.M., Waite, L.L., Warren, H.R., Waterworth, D., Weedon, M.N., Wilkens, L.R., Willenborg, C., Wilsgaard, T., Wojczynski, M.K., Wong, A., Wright, A.F., Zhang, Q., Brennan, E.P., Choi, M., Dastani, Z., Drong, A.W., Eriksson, P., Franco-Cereceda, A., Gådin, J.R., Gharavi, A.G., Goddard, M.E., Handsaker, R.E., Huang, J., Karpe, F., Kathiresan, S., Keildson, S., Kiryluk, K., Kubo, M., Lee, J.-Y., Liang, L., Lifton,

R.P., Ma, B., McCarroll, S.A., McKnight, A.J., Min, J.L., Moffatt, M.F., Montgomery, G.W., Murabito, J.M., Nicholson, G., Nyholt, D.R., Okada, Y., Perry, J.R.B., Dorajoo, R., Reinmaa, E., Salem, R.M., Sandholm, N., Scott, R.A., Stolk, L., Takahashi, A., Tanaka, Toshihiro, van't Hooft, F.M., Vinkhuyzen, A.A.E., Westra, H.-J., Zheng, W., Zondervan, K.T., Heath, A.C., Arveiler, D., Bakker, S.J.L., Beilby, J., Bergman, R.N., Blangero, J., Bovet, P., Campbell, H., Caulfield, M.J., Cesana, G., Chakravarti, A., Chasman, D.I., Chines, P.S., Collins, F.S., Crawford, D.C., Adrienne Cupples, L., Cusi, D., Danesh, J., de Faire, U., den Ruijter, H.M., Dominiczak, A.F., Erbel, R., Erdmann, J., Eriksson, J.G., Farrall, M., Felix, S.B., Ferrannini, E., Ferrières, J., Ford, I., Forouhi, N.G., Forrester, T., Franco, O.H., Gansevoort, R.T., Gejman, P. V., Gieger, C., Gottesman, O., Gudnason, V., Gyllenstein, U., Hall, A.S., Harris, T.B., Hattersley, A.T., Hicks, A.A., Hindorf, L.A., Hingorani, A.D., Hofman, A., Homuth, G., Kees Hovingh, G., Humphries, S.E., Hunt, S.C., Hyppönen, E., Illig, T., Jacobs, K.B., Jarvelin, M.-R., Jöckel, K.-H., Johansen, B., Jousilahti, P., Wouter Jukema, J., Jula, A.M., Kaprio, J., Kastelein, J.J.P., Keinänen-Kiukaanniemi, S.M., Kiemeny, L.A., Knekt, P., Kooner, J.S., Kooperberg, C., Kovacs, P., Kraja, A.T., Kumari, M., Kuusisto, J., Lakka, T.A., Langenberg, C., Le Marchand, L., Lehtimäki, T., Lyssenko, V., Männistö, S., Marette, A., Matise, T.C., McKenzie, C.A., McKnight, B., Moll, F.L., Morris, A.D., Morris, A.P., Murray, J.C., Nelis, M., Ohlsson, C., Oldehinkel, A.J., Ong, K.K., Madden, P.A.F., Pasterkamp, G., Peden, J.F., Peters, A., Postma, D.S., Pramstaller, P.P., Price, J.F., Qi, L., Raitakari, O.T., Rankinen, T., Rao, D.C., Rice, T.K., Ridker, P.M., Rioux, J.D., Ritchie, M.D., Rudan, I., Salomaa, V., Samani, N.J., Saramies, J., Sarzynski, M.A., Schunkert, H., Schwarz, P.E.H., Sever, P., Shuldiner, A.R., Sinisalo, J., Stolk, R.P., Strauch, K., Tönjes, A., Trégouët, D.-A., Tremblay, A., Tremoli, E., Virtamo, J., Vohl, M.-C., Völker, U., Waeber, G., Willemsen, G., Witteman, J.C., Carola Zillikens, M.,

Adair, L.S., Amouyel, P., Asselbergs, F.W., Assimes, T.L., Bochud, M., Boehm, B.O., Boerwinkle, E., Bornstein, S.R., Bottinger, E.P., Bouchard, C., Cauchi, S., Chambers, J.C., Chanock, S.J., Cooper, R.S., de Bakker, P.I.W., Dedoussis, G., Ferrucci, L., Franks, P.W., Froguel, P., Groop, L.C., Haiman, C.A., Hamsten, A., Hui, J., Hunter, D.J., Hveem, K., Kaplan, R.C., Kivimaki, M., Kuh, D., Laakso, M., Liu, Y., Martin, N.G., März, W., Melbye, M., Metspalu, A., Moebus, S., Munroe, P.B., Njølstad, I., Oostra, B.A., Palmer, C.N.A., Pedersen, N.L., Perola, M., Pérusse, L., Peters, U., Power, C., Quertermous, T., Rauramaa, R., Rivadeneira, F., Saaristo, T.E., Saleheen, D., Sattar, N., Schadt, E.E., Schlessinger, D., Eline Slagboom, P., Snieder, H., Spector, T.D., Thorsteinsdottir, U., Stumvoll, M., Tuomilehto, J., Uitterlinden, A.G., Uusitupa, M., van der Harst, P., Walker, M., Wallaschofski, H., Wareham, N.J., Watkins, H., Weir, D.R., Wichmann, H.-E., Wilson, J.F., Zanan, P., Borecki, I.B., Deloukas, P., Fox, C.S., Heid, I.M., O’Connell, J.R., Strachan, D.P., Stefansson, K., van Duijn, C.M., Abecasis, G.R., Franke, L., Frayling, T.M., McCarthy, M.I., Visscher, P.M., Scherag, A., Willer, C.J., Boehnke, M., Mohlke, K.L., Lindgren, C.M., Beckmann, J.S., Barroso, I., North, K.E., Ingelsson, E., Hirschhorn, J.N., Loos, R.J.F., Speliotes, E.K., 2015. Genetic studies of body mass index yield new insights for obesity biology. *Nature* 518, 197–206. <https://doi.org/10.1038/nature14177>

Lopresti, A.L., 2017. Cognitive behaviour therapy and inflammation: A systematic review of its relationship and the potential implications for the treatment of depression. *Aust. New Zeal. J. Psychiatry* 51, 565–582. <https://doi.org/10.1177/0004867417701996>

Löwe, B., Unützer, J., Callahan, C.M., Perkins, A.J., Kroenke, K., 2004. Monitoring Depression Treatment Outcomes With the Patient Health Questionnaire-9. *Med. Care* 42, 1194–1201. <https://doi.org/10.1097/00005650-200412000-00006>

- Lynall, M.-E., Turner, L., Bhatti, J., Cavanagh, J., de Boer, P., Mondelli, V., Jones, D., Drevets, W.C., Cowen, P., Harrison, N.A., Pariante, C.M., Pointon, L., Clatworthy, M.R., Bullmore, E., 2020. Peripheral Blood Cell–Stratified Subgroups of Inflamed Depression. *Biol. Psychiatry* 88, 185–196. <https://doi.org/10.1016/j.biopsych.2019.11.017>
- Mac Giollabhui, N., Ng, T.H., Ellman, L.M., Alloy, L.B., 2020. The longitudinal associations of inflammatory biomarkers and depression revisited: systematic review, meta-analysis, and meta-regression. *Mol. Psychiatry*. <https://doi.org/10.1038/s41380-020-00867-4>
- McIntyre, R.S., Subramaniapillai, M., Lee, Y., Pan, Z., Carmona, N.E., Shekotikhina, M., Rosenblat, J.D., Brietzke, E., Soczynska, J.K., Cosgrove, V.E., Miller, S., Fischer, E.G., Kramer, N.E., Dunlap, K., Suppes, T., Mansur, R.B., 2019. Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults With Bipolar I/II Depression. *JAMA Psychiatry* 1–8. <https://doi.org/10.1001/jamapsychiatry.2019.0779>
- Milaneschi, Y., Kappelmann, N., Ye, Z., Lamers, F., Moser, S., Jones, P.B., Burgess, S., Penninx, B.W.J.H., Khandaker, G.M., 2021a. Association of Inflammation with Depression and Anxiety: Evidence for Symptom-Specificity and Potential Causality from UK Biobank and NESDA Cohorts. *medRxiv*. <https://doi.org/10.1101/2021.01.08.20248710>
- Milaneschi, Y., Lamers, F., Berk, M., Penninx, B.W.J.H., 2020. Depression Heterogeneity and Its Biological Underpinnings: Toward Immunometabolic Depression. *Biol. Psychiatry* 88, 369–380. <https://doi.org/10.1016/j.biopsych.2020.01.014>
- Milaneschi, Y., Lamers, F., Bot, M., Drent, M.L., Penninx, B.W.J.H., 2017a. Leptin Dysregulation Is Specifically Associated With Major Depression With Atypical Features: Evidence for a Mechanism Connecting Obesity and Depression. *Biol. Psychiatry* 81, 807–

814. <https://doi.org/10.1016/j.biopsych.2015.10.023>

Milaneschi, Y., Lamers, F., Penninx, B.W.J.H., 2021b. Dissecting Depression Biological and Clinical Heterogeneity—The Importance of Symptom Assessment Resolution. *JAMA Psychiatry* 362, 2021. <https://doi.org/10.1001/jamapsychiatry.2020.4373>

Milaneschi, Y., Lamers, F., Peyrot, W., Abdellaoui, A., Willemsen, G., Hottenga, J.-J., Jansen, R., Mbarek, H., Dehghan, A., Lu, C., 2016. Polygenic dissection of major depression clinical heterogeneity. *Mol. Psychiatry* 21, 516–522. <https://doi.org/10.1038/mp.2015.86>

Milaneschi, Y., Lamers, F., Peyrot, W.J., Baune, B.T., Breen, G., Dehghan, A., Forstner, A.J., Grabe, H.J., Homuth, G., Kan, C., Lewis, C., Mullins, N., Nauck, M., Pistis, G., Preisig, M., Rivera, M., Rietschel, M., Streit, F., Strohmaier, J., Teumer, A., Van der Auwera, S., Wray, N.R., Boomsma, D.I., Penninx, B.W.J.H., 2017b. Genetic Association of Major Depression With Atypical Features and Obesity-Related Immunometabolic Dysregulations. *JAMA Psychiatry* 74, 1214. <https://doi.org/10.1001/jamapsychiatry.2017.3016>

Möller, H., 2000. Rating depressed patients: observer- vs self-assessment. *Eur. Psychiatry* 15, 160–172. [https://doi.org/10.1016/S0924-9338\(00\)00229-7](https://doi.org/10.1016/S0924-9338(00)00229-7)

Moriarity, D.P., Alloy, L.B., 2021. Back to Basics: The Importance of Measurement Properties in Biological Psychiatry. *Neurosci. Biobehav. Rev.* 123, 72–82. <https://doi.org/10.1016/j.neubiorev.2021.01.008>

Moriarity, D.P., Horn, S.R., Kautz, M.M., Haslbeck, J.M.B., Alloy, L.B., 2020a. How handling extreme C-reactive protein (CRP) values and regularization influences CRP and depression criteria associations in network analyses. *Brain. Behav. Immun.* <https://doi.org/10.1016/j.bbi.2020.10.020>

Moriarity, D.P., van Borkulo, C., Alloy, L.B., 2020b. Inflammatory phenotype of depression symptom structure: A network perspective. *Brain. Behav. Immun.* 87, S48.

<https://doi.org/10.1016/j.bbi.2020.12.005>

Nettis, M.A., Lombardo, G., Hastings, C., Zajkowska, Z., Mariani, N., Nikkheslat, N., Worrell, C., Enache, D., McLaughlin, A., Kose, M., Sforzini, L., Bogdanova, A., Cleare, A., Young, A.H., Pariante, C.M., Mondelli, V., 2021. Augmentation therapy with minocycline in treatment-resistant depression patients with low-grade peripheral inflammation: results from a double-blind randomised clinical trial. *Neuropsychopharmacology* 1–10.

<https://doi.org/10.1038/s41386-020-00948-6>

Ni, G., Zeng, J., Revez, J.A., Wang, Y., Ge, T., Restaudi, R., Kiewa, J., Nyholt, D.R., Coleman, J.R.I., Smoller, J.W., Consortium, S.W.G. of the P.G., Yang, J., Visscher, P.M., Wray, N.R., 2020. A comprehensive evaluation of polygenic score methods across cohorts in psychiatric disorders. *medRxiv* 1–31.

Ohlsson, H., Kendler, K.S., 2019. Applying Causal Inference Methods in Psychiatric Epidemiology. *JAMA Psychiatry* 1–8. <https://doi.org/10.1001/jamapsychiatry.2019.3758>

Osimo, E.F., Baxter, L.J., Lewis, G., Jones, P.B., Khandaker, G.M., 2019. Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of CRP levels. *Psychol. Med.* 49, 1958–1970. <https://doi.org/10.1017/S0033291719001454>

Pistis, G., Milaneschi, Y., Vandeleur, C.L., Lasserre, A.M., Penninx, B.W.J.H., Lamers, F., Boomsma, D.I., Hottenga, J., Marques-Vidal, P., Vollenweider, P., Waeber, G., Aubry, J., Preisig, M., Kutalik, Z., 2021. Obesity and atypical depression symptoms: findings from Mendelian randomization in two European cohorts. *Transl. Psychiatry* 11, 96.

<https://doi.org/10.1038/s41398-021-01236-7>

R Core Team, 2017. R: A language and environment for statistical computing.

Raison, C.L., Rutherford, R.E., Woolwine, B.J., Shuo, C., Schettler, P., Drake, D.F., Haroon, E., Miller, A.H., 2013. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. *JAMA Psychiatry* 70, 31–41. <https://doi.org/10.1001/2013.jamapsychiatry.4>

Robinaugh, D.J., Hoekstra, R.H.A., Toner, E.R., Borsboom, D., 2020. The network approach to psychopathology: a review of the literature 2008–2018 and an agenda for future research. *Psychol. Med.* 50, 353–366. <https://doi.org/10.1017/S0033291719003404>

Rush, A.J., Fava, M., Wisniewski, S.R., Lavori, P.W., Trivedi, M.H., Sackeim, H.A., Thase, M.E., Nierenberg, A.A., Quitkin, F.M., Kashner, T.M., Kupfer, D.J., Rosenbaum, J.F., Alpert, J., Stewart, J.W., McGrath, P.J., Biggs, M.M., Shores-Wilson, K., Lebowitz, B.D., Ritz, L., Niederehe, G., for the STAR\*D Investigators Group, 2004. Sequenced treatment alternatives to relieve depression (STAR\*D): rationale and design. *Control. Clin. Trials* 25, 119–142. [https://doi.org/10.1016/S0197-2456\(03\)00112-0](https://doi.org/10.1016/S0197-2456(03)00112-0)

Rush, A.J., Trivedi, M.H., Wisniewski, S.R., Nierenberg, A.A., Stewart, J.W., Warden, D., Niederehe, G., Thase, M.E., Lavori, P.W., Lebowitz, B.D., McGrath, P.J., Rosenbaum, J.F., Sackeim, H.A., Kupfer, D.J., Luther, J., Fava, M., 2006. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR\*D Report. *Am. J. Psychiatry* 163, 1905–1917. <https://doi.org/10.1176/appi.ajp.163.11.1905>

Simmons, W.K., Burrows, K., Avery, J.A., Kerr, K.L., Taylor, A., Bodurka, J., Potter, W., Teague, T.K., Drevets, W.C., 2018. Appetite changes reveal depression subgroups with



distinct endocrine, metabolic, and immune states. *Mol. Psychiatry* 1–12.

<https://doi.org/10.1038/s41380-018-0093-6>

Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., Liu, B., Matthews, P., Ong, G., Pell, J., Silman, A., Young, A., Sprosen, T., Peakman, T., Collins, R., 2015. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLOS Med.* 12, e1001779. <https://doi.org/10.1371/journal.pmed.1001779>

Timpson, N.J., Nordestgaard, B.G., Harbord, R.M., Zacho, J., Frayling, T.M., Tybjaerg-Hansen, A., Davey Smith, G., 2011. C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal Mendelian randomization. *Int. J. Obes.* 35, 300–308. <https://doi.org/10.1038/ijo.2010.137>

van Borkulo, C., Boschloo, L., Borsboom, D., Penninx, B.W.J.H., Waldorp, L.J., Schoevers, R.A., 2015. Association of Symptom Network Structure With the Course of Depression. *JAMA Psychiatry* 72, 1219–1226. <https://doi.org/10.1001/jamapsychiatry.2015.2079>

van Eeden, W.A., van Hemert, A.M., Carlier, I.V.E., Penninx, B.W.J.H., Lamers, F., Fried, E.I., Schoevers, R., Giltay, E.J., 2020. Basal and LPS-stimulated inflammatory markers and the course of individual symptoms of depression. *Transl. Psychiatry* 10, 235. <https://doi.org/10.1038/s41398-020-00920-4>

White, J., Kivimäki, M., Jokela, M., Batty, G.D., 2017. Association of inflammation with specific symptoms of depression in a general population of older people: The English Longitudinal Study of Ageing. *Brain. Behav. Immun.* 61, 27–30. <https://doi.org/10.1016/j.bbi.2016.08.012>

Williams, D.R., Rhemtulla, M., Wysocki, A.C., Rast, P., 2019. On Nonregularized Estimation of Psychological Networks. *Multivariate Behav. Res.* 0, 1–23.

<https://doi.org/10.1080/00273171.2019.1575716>

Wittenberg, G.M., Stylianou, A., Zhang, Y., Sun, Y., Gupta, A., Jagannatha, P.S., Wang, D., Hsu, B., Curran, M.E., Khan, S., Chen, G., Bullmore, E.T., Drevets, W.C., 2020. Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. *Mol. Psychiatry* 25, 1275–1285.

<https://doi.org/10.1038/s41380-019-0471-8>

Wray, N.R., Lin, T., Austin, J., McGrath, J.J., Hickie, I.B., Murray, G.K., Visscher, P.M., 2020.

From Basic Science to Clinical Application of Polygenic Risk Scores: A Primer. *JAMA*

*Psychiatry*. <https://doi.org/10.1001/jamapsychiatry.2020.3049>

## TABLES & FIGURES

### Tables

*Table 1. Baseline characteristics of MARS, STAR\*D, and UK Biobank samples*

	<b>MARS</b>	<b>STAR*D</b>	<b>UK Biobank</b>
N	1,058	1,143	110,010
Sex			
Women, N (%)	563 (53.2%)	676 (59.1%)	61,212 (55.6%)
Men, N (%)	495 (46.8%)	467 (40.9%)	48,798 (44.4%)
Age in years			
Mean (SD)	47.8 (14.4)	43.2 (13.6)	56.2 (7.7)
Range	18-87	18-75	39-72
Study location	Germany	United States	United Kingdom
Study population	MDD inpatients	MDD outpatients	General population
CRP PRS			
Mean (SD)	-0.01 (1.00)	0.00 (1.00)	-0.01 (1.00)
Range	-3.14-3.15	-3.21-2.94	-4.58-4.21
IL-6 PRS			
Mean (SD)	0.00 (1.00)	0.00 (1.00)	0.00 (1.00)
Range	-3.33-3.34	-3.41-3.94	-4.07-3.92
IL-10 PRS			
Mean (SD)	0.00 (1.00)	0.00 (1.00)	0.00 (1.00)
Range	-3.11-3.24	-3.28-3.13	-4.35-4.60
TNF-a PRS			
Mean (SD)	0.00 (1.00)	0.00 (1.00)	0.00 (1.00)
Range	-3.61-3.67	-3.35-3.52	-4.17-4.51
BMI PRS			
Mean (SD)	-0.02 (1.01)	0.00 (1.00)	-0.04 (1.00)
Range	-3.02-4.06	-3.04-3.20	-4.53-3.96
PHQ-9 sum-score			
Mean (SD)	-	-	2.7 (3.6)
Range	-	-	0-27
Missing, N (%)	-	-	351 (0.3)
HAM-D sum-score			
Mean (SD)	23.8 (5.9)	22.4 (4.9)	-
Range	5-42	13-38	-
Missing, N (%)	6 (0.6%)	0 (0%)	-
Depressed mood			
Mean (SD)	3.05 (0.88)	2.59 (0.77)	0.23 (0.56)
Range	0-4	0-4	0-3
Anhedonia			
Mean (SD)	3.63 (0.68)	2.54 (0.76)	0.26 (0.56)
Range	0-4	0-4	0-3
Sleep problems			
Mean (SD)	3.46 (2.00)	3.42 (1.77)	0.71 (0.99)
Range	0-6	0-6	0-3

	<b>MARS</b>	<b>STAR*D</b>	<b>UK Biobank</b>
<b>Fatigue</b>			
Mean (SD)	1.49 (0.68)	1.68 (0.55)	0.66 (0.81)
Range	0-2	0-2	0-3
<b>Changes in appetite</b>			
Mean (SD)	0.77 (0.66)	0.68 (0.80)	0.25 (0.62)
Range	0-2	0-2	0-3
<b>Psychomotor changes</b>			
Mean (SD)	1.44 (0.96)	1.42 (0.72)	0.07 (0.34)
Range	0-4	0-4	0-3
<b>Suicidality</b>			
Mean (SD)	1.35 (1.15)	0.94 (0.85)	0.05 (0.28)
Range	0-4	0-4	0-3

*Note:* MDD=Major Depressive Disorder, SD=Standard deviation, PHQ-9=Patient Health Questionnaire-9, HAM-D=Hamilton Rating Scale for Depression.

**Table 2. PRS-symptom edge consistency criteria (C) across network analyses**

PRS-symptom edges	MARS		STAR*D		UK Biobank		FGL consistency (C2)
	FGL (C1)	Model search (C3)	FGL (C1)	Model search (C3)	FGL (C1)	Model search (C3)	
<b>CRP</b>							
Anhedonia	-0.016 (67%)		-0.043 (95%)		-0.002 (60%)		Yes
Depressed mood	-0.009 (57%)		0.045 (94%)				
Sleep problems*	-0.02 (75%)		0.031 (84%)				
Fatigue	0.053 (98%)		0.025 (79%)		0.011 (100%)		Yes
Changes in appetite*	-0.034 (89%)		-0.043 (94%)		0.003 (91%)	0.013 (73%)	Yes
Psychomotor changes	0.039 (91%)		0.001 (53%)				
Suicidality	-0.02 (74%)		-0.038 (88%)				
<b>IL-6</b>							
Anhedonia	-0.047 (97%)						
Depressed mood	-0.001 (52%)						
Sleep problems*			-0.02 (82%)				
Fatigue	0.012 (72%)						
Changes in appetite*	-0.032 (87%)		0.032 (85%)				
Psychomotor changes							
Suicidality	0.053 (95%)		-0.029 (83%)				
<b>IL-10</b>							
Anhedonia	0.008 (67%)		-0.005 (66%)				
Depressed mood			-0.002 (52%)				
Sleep problems*			0.014 (72%)				
Fatigue			0.007 (66%)				
Changes in appetite*	0.021 (80%)						
Psychomotor changes	0.015 (66%)		0.033 (90%)				
Suicidality			0.054 (99%)				
<b>TNF-<math>\alpha</math></b>							
Anhedonia	0.054 (96%)		0.013 (66%)				
Depressed mood	-0.017 (66%)		-0.017 (75%)				
Sleep problems*	-0.005 (57%)		0.005 (68%)				
Fatigue	0.016 (65%)		0.032 (91%)		0.002 (58%)		Yes
Changes in appetite*	-0.015 (70%)		0.023 (75%)				

PRS-symptom edges	MARS		STAR*D		UK Biobank		FGL consistency (C2)
	FGL (C1)	Model search (C3)	FGL (C1)	Model search (C3)	FGL (C1)	Model search (C3)	
Psychomotor changes	0.008 (63%)		0.008 (59%)				
Suicidality			0.047 (94%)				
<b>BMI</b>							
Anhedonia	0.036 (91%)		0.033 (86%)			-0.010 (63%)	
Depressed mood							
Sleep problems*	0.06 (99%)		0.055 (97%)				
Fatigue	-0.016 (74%)						
Changes in appetite*			-0.031 (87%)		0.054 (100%)	0.066 (100%)	
Psychomotor changes	0.003 (55%)		-0.023 (83%)				
Suicidality	0.021 (75%)		0.04 (91%)				

*Note:* Cell values reflect edge weights (i.e., partial correlation coefficients) and the percentage of 500 bootstrap estimations that edges were present. Estimates are restricted to those edges, for which >50% of bootstrapped samples were non-zero and directionally consistent (i.e., criteria 1 & 3). \* Changes in appetite and sleep problems are measured as composite symptoms in UK Biobank, but as loss of appetite and insomnia in MARS and STAR\*D samples.

## Figure Titles and Legends

### ***Figure 1. Study design and analysis pipeline***


Legend: BIC=Bayesian information criterion; CV=cross-validation; PC=principal component (or multi-dimensional scaling component used for MARS & STAR\*D);  $\lambda$ =PRS-CS tuning parameter.

### ***Figure 2. Estimated FGL networks across samples***

Legend: Networks are visualised with the *qgraph* package. Blue lines indicate positive and red lines negative associations, respectively, with larger associations displayed with thicker lines. Circles around nodes display node predictability, which can be interpreted similar to explained variance. Maximum size of edge associations is 0.55. As the primary focus of this investigation was to identify consistent PRS-symptom associations, we manually unfaded edges between PRSs and symptoms if these edges met quality criteria 1 and 2 (see Table 2). Changes in appetite and sleep problems are measured as composite symptoms in UK Biobank, but as loss of appetite and insomnia in MARS and STAR\*D samples.


### ***Figure 3. Bootstrapped 95% quantile intervals of PRS-symptom edges using FGL estimation***

Legend: Bootstrapped 95% quantile intervals (i.e., 95% of the distribution of raw bootstrapped edge estimates) are highlighted as shaded area for each edge. Black points indicate the raw FGL sample estimate while red points indicate the raw bootstrapped mean estimate. Edges are indicated on the y-axis and sorted by mean edge weight across samples in descending order.







MARS



STAR\*D



UK Biobank



**A: Depressive Symptoms**

- 1: Depressed mood
- 2: Anhedonia
- 3: Sleep problems
- 4: Fatigue
- 5: Changes in appetite
- 6: Psychomotor changes
- 7: Suicidality

**B: Polygenic Risk Scores**

- 8: CRP
- 9: IL-6
- 10: IL-10
- 11: TNF-a
- 12: BMI

● Bootstrap Mean    ● Sample

